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ABSTRACT 
 
The purpose of this study was to establish empirical evidence on risk factors influencing 
drug-resistant tuberculosis (DR-TB) in Swaziland. Globally factors have been identified 
and specific programmatic interventions were implemented to counter the emergence of 
DR-TB, but the case still remains with Swaziland. The research question was “What are 
the risk factors influencing the epidemiology of DR-TB patients enrolled for treatment at 
the National Tuberculosis Referral Hospital? The research objectives were to 
investigate factors that influence the emergence of DR-TB in Swaziland, to establish the 
relationship between DR-TB and HIV and to develop a poster that will exhibit the 
findings on the study on risk factors influencing the epidemiology of DR-TB. A mixed 
method was used. A qualitative  study of participants using the in-depth one on one  
interview with a grand tour question “ What are the risk factors that resulted in you 
having DR-TB” and  probing questions. The quantitative retrospective part was utilised 
to review medical records. Convenience sampling was utilised to recruit participants 
using an interview guide to collect data and random sampling for the quantitative aspect 
using a checklist to collect data.  
 
Risk factors influencing the development of DR-TB were identified to be previous 
treatment with anti-tuberculosis drugs, human immunodeficiency virus (HIV). The 
findings showed that the prevalence of HIV in DR-TB was 61% for HIV positive and 
39% for negative and the quantitative data showed 77% HIV positive and 23% negative 
to HIV.  Lack of education for patients and their families on precautionary measures to 
take when caring for a family member, and what to do in cases of developing side 
effects. 
 This study concludes that both the need to ensure that bacteriologically confirmed 
patients are initiated to treatment, adhere to their treatment and complete treatment and 
due to the number of direct cases being infected with DR-TB ensuring that infection 
control strategies are put in place at work and at home settings.  
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CHAPTER 1 
 
ORIENTATION OF THE STUDY 
 
“Every sickness has an alien quality, a feeling of invasion and loss of control that is 
evident in the language we use about it.” 
Siri Hustvedt  
 
1.1 INTRODUCTION 
 
The epidemic of drug-resistant tuberculosis (DR-TB) is a public health emergency that 
threatens to destabilise global TB control. Although TB incidence and mortality are 
decreasing in several parts of the world, the overall prevalence of multidrug-resistant 
tuberculosis (MDR-TB) is increasing in many high-burden countries, particularly in 
Africa. In 2008, the World Health Organization (WHO) estimated that more than 
440,000 individuals had multidrug resistant tuberculosis (MDR-TB) worldwide. Such 
patients are resistant to at least isoniazid and rifampicin, the most effective anti-TB 
drugs (WHO 2008:59). 
 
Calligaro and Dheda (2013:9) state that TB is the second most common cause of death 
from infectious diseases in the world. The absolute number of tuberculosis cases has 
been decreasing since 2005 and new cases since 2002. In 2007, the country with the 
highest estimated incidence rate of TB in Southern African Developing Countries 
(SADC) was Swaziland, with 1200 cases per 100,000 people, from a total population of 
+-1,100,000. India had the largest total incidence, with an estimated 2.0 million new 
cases (Calligaro & Dheda 2013:9). The incidence of TB varies with age, as in Africa, TB 
primarily affects adolescents and young adults. However, in countries where TB has 
gone from high to low incidence, such as the United States (US) where national data 
shows a steady decline, and currently TB is mainly a disease of older people, or of the 
immune compromised (Epidemiology of Tuberculosis 2013:1). 
 
An understanding of the epidemiology of Mycobacterium TB which is critical for effective 
control of TB is essential. It is also useful for all TB program staff motivated by the 
Ministry of health, ranging from health care workers and public health representatives to 
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TB program managers in analysing and making practical use of data, assessing current 
and evolving trends in TB morbidity, identifying risk groups and associated risk factors, 
and determining where to allocate staff and resources. Conducting research to identify 
risk factors that exposes TB patients to DR-TB seem imperative in order to add to the 
current studies done especially by medical doctors to minimise its effect on the quality 
of life for patients suffering from TB (Epidemiology of Tuberculosis 2013:1).  
 
Therefore this study envisages investigating what risk factors are there which influences 
prevalence and the incidence of DR-TB especially on patients already enrolled on 
treatment. 
 
1.2 PHASES OF THE STUDY 
 
The study was conducted in three phases as exhibited in figure 1.1. These phases 
included firstly conceptualisation and planning through comprehensive literature review. 
The second phase involved design and planning and the third phase involved empirical 
implementation of the research process. 
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Background  
Background  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Phases of the study 
Conceptualising and planning 
Background  
Research questions and 
hypothesis 
Literature review 
Theoretical foundation 
 
Design and planning 
Research design 
Data collection 
Data analysis 
Ethical considerations 
PHASE 3 
Empirical phase 
Population and sampling 
Data collection  
 
Distribution of questionnaire 
Analysis and interpretation 
 
Discussions 
Validity and reliability 
PHASE 1 PHASE 2 
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All three of these phases demonstrated the pathway in which the research was followed 
from the beginning to the end of the study process. 
 
The first phase was a very brief phase of the study and it involved conceptualising and 
planning. A comprehensive review of the literature using sources such as journals, 
articles, research and discipline books, and the internet was undertaken for contextual 
understanding of risk factors associated with DR-TB. The literature review included 
studies that were conducted internationally, sub-Saharan countries, Africa, and 
Swaziland  
 
The second phase involved constructing the research methodology, which focused on 
both quantitative and qualitative non-experimental, contextual research design, 
theoretical framework and the research methods to be used, which included study 
population and sampling, data collection and data analysis.  In this phase the 
researcher gained the privilege of entering the DR-TB hospitals and developing a 
rapport with the facility management and staff.  
 
During the third phase, the researcher engaged in discussion, devising conclusions and 
recommendations based on the study findings.  
 
1.3 BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM  
 
Multidrug resistant tuberculosis (MDR-TB) is caused by the transmission of multidrug 
resistant Mycobacterium tuberculosis strains in new cases, or by the selection of single 
drug resistant strains induced by previous treatment (Faustini 2005:1-2). The 
resurgence of TB has been attributed to the human immunodeficiency virus (HIV) 
epidemic, immigration, and DR Emergence of DR-TB is a global threat that poses a 
threat to human kind. Drug resistant tuberculosis has caused the treatment of TB to be 
more complicated resulting in poor treatment outcomes leading to patients staying 
longer on treatment and longer exposure to toxic drugs that cause countless side 
effects to the patients such as hearing loss (Faustini 2005:1). 
 
According to the Swaziland National Tuberculosis Manual (2013:14), Swaziland has 
reported an increase in TB incidence, with new cases rising from 1458 in 1995 to 11057 
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in 2010. Tuberculosis remains a major public health challenge in the kingdom of 
Swaziland with an estimated 20% of institutional deaths attributable to the disease. With 
an estimated TB incidence of 1,287 per every 100,000 of its population, Swaziland is 
one of the countries with the highest TB incidence in the world. Compared to a 1990 
level of 267 new cases of all forms per 100,000 populations per year, TB incidence had 
increased six-fold, by 2010, while incidence of the infectious cases (sputum smear 
positive pulmonary TB cases) tripled in the same period which could be due to improved 
diagnostic measures such as the GenXpert. The GenXpert is a new diagnostic machine 
that has made the testing of both TB and DR-TB easier through ensuring early 
diagnosis within four hours and enables early treatment of patients (The National 
Tuberculosis Manual 2013:14). 
 
The country’s co-infection rate also does not assist as it is reportedly at 80%. 
Susceptible TB treatment takes a minimum of six months duration and DR-TB treatment 
takes at least 18 months of treatment which includes   three to eight months of an 
injectable.  
 
The Global response to TB was the STOP TB Strategy that Swaziland also adopted. 
This strategy puts in measures that encourage TB patients to adhere to TB treatment 
throughout their therapy. This included among others the introduction of community 
treatment supporters who were linked to a patient to ensure that the supporter 
motivates the patient to reach the treatment end line. (Stop TB Strategy 2011:5). 
 
In the Manzini region in 2011, Swaziland declared TB a national emergency. The Prime 
Minister’s declaration of TB as a national catastrophe resulted in escalated efforts 
against the pandemic, the NTCP put in place measures including placing adherence 
officers at different TB diagnostic facilities that were responsible for tracing treatment 
interrupters and defaulters. Integration of HTS (HIV Testing Services) in TB Clinics to 
minimise loss of patients through departmental referrals. The introduction of screening 
of all HIV positive patients at all voluntary counselling and Testing (VCT’s) centres and 
introduction of TB screening at all facility entry points. This was to ensure early 
identification, early diagnosis and early treatment to prevent transmission and 
graduation from TB to DR-TB. Treatment for DR TB is more toxic, lengthy, and 
expensive than for drug susceptible TB and treatment success rates which is cure plus 
treatment completion are usually lower. Failure to adhere to susceptible TB treatment 
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may cause an increased incidence rate as a result of primary infection in the 
households and community. Poor adherence to TB treatment may lead to development 
of DR-TB as a result of exposure to drugs without completion of course duration. 
 
The emergence and spread of MDR TB, extensively drug-resistant (XDR) TB, and more 
recently, totally drug-resistant TB poses a threat to global TB control (WHO 2013:1). 
 
Tuberculosis remains one of the leading causes of morbidity and mortality worldwide, 
and resistance to commonly used anti-TB drugs is increasing. As a result DR-TB has 
become a major public health challenge confronting the population in Swaziland. In 
Swaziland about 40-50 cases of DR-TB are diagnosed on monthly basis. According to 
the DRS in 2009 done by the NTCP, drug resistant TB is associated with unfavorable 
treatment outcomes which are high morbidity and mortality, making Swaziland among 
the first highest burden of DR-TB globally. In comparison with other neighboring 
countries especially SA, which has the fifth highest burden of DR-TB globally, with an 
incidence of ~2% of new patients and ~7% of retreatment cases; of these, 5-10% have 
Extensive Drug Resistance (XDR-TB). 
 
The World Health Organization (WHO 2013) statistics show that almost half a million 
new cases of MDR-TB develop every year, of which approximately 40 000 in more than 
80 countries globally are thought to be extensively DR-TB. Limited laboratory capacity 
and lack of widespread drug susceptibility in resource-poor settings mean that only a 
fraction of that number are correctly diagnosed and started on treatment (WHO 2013). 
This reservoir of undiagnosed and/or untreated DR-TB is largely responsible for driving 
ongoing person-to-person transmission. Treatment defaulters, delays in initiating 
treatment, inadequate bed capacity, and poor infection control in healthcare facilities are 
also important contributors. According to Calligaro and Dheda (2013:9), identifying and 
dealing with the threat of DR-TB is critical.   
 
Firstly, DR-TB has poorer treatment outcomes when compared to drug-sensitive TB. Of 
the estimated half a million MDR-TB patients started globally on treatment in 2009, only 
48% were treated successfully. Outcomes for XDR-TB are even worse. Although the 
overall success rate for XDR-TB in a recent meta-analysis was reported as 44%, a 
retrospective study from SA by Ghandi et al showed that fewer than 20% of patients 
with XDR-TB culture converted within six months of initiation of treatment. This poor 
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outcome was independent of HIV status. Secondly, DR-TB involves a longer duration of 
treatment with less potent but more toxic medications, and higher relapse rates occur. 
Lastly, DR-TB treatment is considerably more expensive than standard TB treatment. 
Despite only comprising 2.2% of the case burden of TB in SA, DR-TB consumes a third 
of the total estimated national TB budget for the country (Calligaro & Dheda 2013:9).  
 
Porwal, Kaushik, Makkar, Banavaliker, Hanif, Singla (2013:6) state that among the risk 
factors associated with progression of TB to drug resistance is chest x-ray cavitation’s, 
with highest cavitation being associated with XDR-TB. Four factors showed significant 
associations with worsening drug resistant which are family history of TB, socio-
economic status, comorbidities and previous intake of second line injectable drugs. 
According to Libo, Wu Qunhong, Gao Lijun, Hao et al (2011:12), a conclusion made 
was that inappropriate treatment is the most important influencing factor of DR-TB. The 
authors further contend that increasing people's awareness of TB, early detection and 
appropriate treatment of patients with TB should become a priority, which requires 
strong commitment and collaboration among health organisations and greater 
compliance with TB treatment guidelines by service providers and patients. 
 
According to Espinal, Laserson, Camacho, Fusheng, Kim, Tlali et al (2001:22), patient 
characteristics including age and HIV infection are also believed to influence the 
dynamics of transmission of DR organisms.  
 
1.3.1 Source of the research problem  
 
The researcher, working as a coordinator of DR-TB facilities, observed that there is a 
notable increase in the number of patients confirmed with DR-TB in Swaziland. The 
development of DR-TB may result due to various reasons which could be inappropriate 
treatment, patients not taking the correct dosage or poor adherence to prescribed TB 
treatment. However, the high incidence of DR-TB seems to be associated with some 
risk factors which expose patients to infection with drug-resistant TB. More so TB is a 
high health challenge in the country because DR-TB has poorer treatment outcomes, 
takes longer period to treat, thereby expensive to treat, more toxic drugs, and uses a 
majority of the national health budget for TB prevention and treatment (Porwal et al 
2013:6). It makes it crucial to empirically investigate what these factors are and how 
they can therefore be identified, addressed and minimised. 
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1.3.2 Research problem  
 
A research problem is “a situation or condition that is enigmatic, perplexing or troubling 
that can be investigated through disciplined enquiry” (Polit & Beck 2012:34).  
 
Espinal et al (2001:23) state that global statistics on the determinants of drug-resistant 
tuberculosis (TB) based on representative data seem to be inadequate. 
 
Although Swaziland, is a country with a population of about 1,100,000 people in 
coverage of 17,300 square kilometers of land square meters, has reported a high 
incidence rate over the years.  Swaziland prior to mid-1980 the country appeared to be 
winning the battle against TB but with emergence of other diseases such as HIV the 
tables turned around and TB became more prevalent in the country. Health facilities 
were burdened by more 11057 new TB patients in 2010 according to the National TB 
Control Program National Strategic Plan (2014). According to the last DR-TB survey 
done in the country, Swaziland had 3.3% of these new cases resulting in DR-TB and 
33.9% of re-treatment cases ending up being DR-TB cases.  
 
Swaziland has been putting different measures in the fight against TB and DR-TB. 
However, there is currently not enough scientific evidence in the country to assist in 
taking programmatic decisions and in the development of policies that are country 
specific to deal with risk factors that patients are exposed to. The measures currently in 
place are based on what the global experts concluded based on different studies done 
in various countries that may not have similar characteristics as Swaziland.  
 
The NTCP, health care workers and the patients are truly not aware of what risk factors 
in Swaziland fuel the emergence of drug resistance TB. Studies on the construct under 
investigation such as this one are needed to actually validate assumptions by Global 
bodies such as the WHO which will in turn result in country specific interventions that 
are effective in a country such as Swaziland. Though the country has between 2011 
and 2015 shown a gradual decline in TB patients, the same cannot be said for DR-TB 
which has shown a gradual increase. This is a major concern because a resistant 
infection results in high mortality, can spread to others and ultimately imposes huge 
costs to individuals and society. 
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A study conducted by Frieden, Sterling, Pablos-Mendez, Kilburn, Cauthen and Dooley 
(1993:2) in New York conclude that “DR-TB patients are rapidly increasing, as a result 
of  previous TB treatment history, HIV infection and drug use”. Therefore empirical 
measures to identify high risk factors in order to control and reduce DR-TB are urgently 
needed. 
 
1.4 PURPOSE OF RESEARCH 
 
The purpose of this study was to determine the risk factors influencing epidemiology of 
DR-TB patients enrolled for treatment at the hospital.  
 
The researcher also aimed to conduct qualitative discussions with individuals to 
investigate the risk factors associated with the development of drug resistant TB and 
retrospective review of drug resistant patient’s records.  
 
1.5 OBJECTIVES OF THE STUDY 
 
The objectives of this study were to 
 
• explore and describe the risk factors influencing the epidemiology of DR-TB 
amongst patients enrolled on DR-TB 
• identify risk factors influencing the epidemiology of DR-TB amongst patients 
enrolled on DR-TB treatment 
• develop a poster that will exhibit the research process undertaken and the 
findings 
 
 1.6 RESEARCH QUESTION 
 
The research question of this study was formulated based on the PICO approach which 
is discussed in detail in chapter 3.  
 
The research question for this study was: 
 
“What are the risk factors that influence DR-TB occurrence among patients enrolled on 
DR-TB treatment?” 
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1.7 HYPOTHESIS OF THE STUDY 
 
A research hypothesis (H1 or Ha) is the alternative to the null and is according to Creswell 
(2013:143), the prediction that a researcher makes about the expected outcomes of the 
relationship among study variables. These hypotheses are numeric estimates of the 
values within populations which are based on the data collected from the given 
samples. Testing of hypotheses employs statistical procedures in which the researcher 
draws inferences about the population which is used in the study sample (Creswell 
2013:143). 
 
A null hypothesis of this study was that there is no association between the independent 
and dependent variables. That there will be no increased awareness of risk factors 
influencing DR-TB, no interventions put in place and no reduction of DR-TB. 
 
The research hypothesis of this study was that ‘There are increased high risk factors 
influencing development of DR-TB among patients enrolled on DR-TB than among 
those with susceptible TB. 
 
1.8 SIGNIFICANCE OF THE STUDY 
 
Different assumptions have been made on multiple risk factors that contribute to the 
existing DR-TB prevalence globally. The findings of this study will assist clinicians, 
policy makers and researchers to gain insight on the major factors contributing to the 
high prevalence of DR-TB in the country. The findings of this study will also be used as 
a learning process on the risk factors resulting in the high prevalence of Drug resistant 
TB patients of the country in the region. It will increase awareness to stakeholders and 
decision makers on the risks predisposing the public to infection with DR-TB and in turn 
inform the staff that runs the National TB control program to set up systems that will 
minimise the rate of exposure to these risks, in turn less transmission will occur 
amongst those healthy/without clinical symptoms. 
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1.9 DEFINITION OF KEY CONCEPTS 
 
Drug resistance tuberculosis 
 
The WHO (2013:12) defines drug-resistant TB as resistance to Antimicrobial – also 
known as drug resistance that occurs when microorganisms such as bacteria, viruses, 
fungi and parasites that render the medications used to cure the infections they cause 
ineffective. Faustini, Hall and Perruci (2006:159) define drug-resistant TB as a disease 
that is resistant to isoniazid (H) and rifampicin (R). Resistance to one drug may become 
resistance to two or more drugs.  
 
In this study, drug resistance refers to resistance of the TB bacilli to anti TB drugs due 
to mutation of the bacteria as evidenced by lack of improvement even if the patient is on 
treatment. 
 
Epidemiology 
 
Epidemiology according to Stanhope and Lancaster (2011:G-11), is defined as the 
study determining and influencing the frequency and  distribution of disease, injury and 
other health related events and their causes in a defined human population. 
 
In this study epidemiology refers to the distribution of new infections, and current 
infections with DR-TB identified on patients who come monthly for treatment at the 
referral hospital. 
 
Enrolment 
 
The Oxford Advanced Learner’s Dictionary (2010:349) defines enrolment as an act of 
officially joining or a state of being enrolled, recorded or listed. 
 
In this study enrolment refers to initiation of a patient on DR-TB treatment. 
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Influence 
 
The Oxford Advanced Learner's Dictionary (2010:450) defines influence as a positive or 
negative effect that somebody or something has on the way a person thinks or behaves 
or on the way that something works or develops. Influence can be good or bad (on 
someone or something). 
 
In this study influence means either the positive or negative factors that predispose 
patients to DR-TB infection.  
 
Patient 
Patient is defined by Freshwater and Maslin-Prothero (2005:440) as a person who is 
physically or mentally ill and is undergoing nursing and medical treatments for healing.  
The term ‘patient’ is further referred to a person who is receiving needed professional 
services that are directed by a licensed practitioner of the healing arts toward 
maintenance, improvement or protection of health or lessening of illness, disability or 
pain (US Centers for Medicare and Medicaid services) 
 
In this study, patient refers to the person who has been infected with TB and has been 
initiated on drug-resistant TB treatment. 
 
Risk factors 
 
According to Stanhope and Lancaster (2011:G27), ‘risk factors’ refers to the disease 
precursor, the presence of which is associated with higher than average mortality. 
Disease precursors include demographic variables, certain everyday health practices, 
family history of disease and some physiologic changes. 
 
In this study, ‘risk factors’ refers to the situations or health practices and behaviors that 
predisposes one to infection resulting in the TB disease leading to drug resistance. 
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Treatment 
 
‘Treatment’ according to Freshwater & Maslin-Prothero (2005:622), is any medical, 
surgical or psychological care of a person aimed at relieving symptoms of a disease or 
injury or curing the condition. 
 
In this study, ‘treatment’ refers to the treatment given to DR-TB patients at the National 
DR-TB Hospital. 
 
1.10 CONTEXT OF THE STUDY. 
 
In Swaziland there are seven DR-TB initiating sites that offer DR-TB treatment to 
patients diagnosed with DR-TB. This study was conducted at one of these sites which is 
a central DR-TB site where complicated cases are referred to. It is a National TB 
Referral Hospital setting in Swaziland, that initiates and provide monthly reviews and 
follow ups of DR-TB patients The staff in the facility includes medical officers, 
professional nurses, nursing assistants, data clerks, and support staff. It has bed 
capacity of 100 patients per zone and has a turnover of about 30 patients daily.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2   The drug resistant facilities in Swaziland 
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1.11 METATHEORETICAL ASSUMPTIONS  
 
Assumptions are basic principles that are assumed to be true, based on logic and 
reason, without proof or verification (Polit & Beck 2008:14). Sources of assumptions 
include: universally accepted truths; established theories and research findings; and 
verified medical practice. In research studies, assumptions are embedded in the 
philosophical base of the researcher, as well as in the study design and the 
interpretation of findings conducted by the researcher (Burns & Grove 2007:39). The 
recognition of these assumptions by the researcher is able to be strength and not a 
weakness. In this study, ontological, epistemological and methodological assumptions 
were reflected upon, which informed the way in which the study was framed. 
 
Ontological assumptions 
 
According to Mouton and Marais (1994:11, 12), ontological assumptions refer to the 
study of the state of being, or of concepts of reality. The ontological assumptions 
regarding reality which underpin this study have been that: 
 
• DR-TB epidemiology is influenced by certain health related and social factors 
• Human beings are diverse in how they think, act or behave in response 
especially to chronic illnesses 
• Multiple realities exist with regard to the risk factors that influence DR-TB 
occurrence among patients and this can be captured by means of asking 
questions from people experiencing a particular phenomenon as how it is real to 
them 
 
Epistemological assumptions 
 
Epistemological assumptions are statements that embody the ideal of science, namely 
the quest for truth and knowledge (Mouton & Marais 1994:14-15). In this regard, the 
epistemological assumptions are as follows:  
 
• Narrative data can elicit an understanding of the meanings that TB patients 
attach to what it means to default on treatment or be exposed to risks factors. 
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• Although it is difficult to ascertain when the truth has been attained, it is, 
however, necessary to strive for reality as close as possible. 
• Theories inductively generated from data are likely to offer insight, knowledge, 
enhance understanding and provide a meaningful guide to action, including 
nursing practice.  
 
Methodological assumptions 
 
Methodological assumptions, according to Mouton and Marais (1994:15-16), provide the 
‘how’ of research. In other words, how should research be planned, structured and 
executed to comply with the criteria of science. It refers to the logic of implementing 
scientific methods in the study of reality. Methodological assumptions regarding this 
study are as follows: 
 
• Human beings use language to attach meaning to phenomena and communicate 
the meanings to others. 
• Qualitative research supports naturalistic inquiry to collect narrative data on 
reality, which is constructed by people. 
• Deductive reasoning is helpful to draw conclusions from the general premise of 
phenomena to specific situations. 
 
Burns and Grove (2007:37) conclude that assumptions are embedded (unrecognised) in 
thinking and behavior, and uncovering these assumptions requires introspection and a 
strong knowledge base in the particular field of study. 
 
1.12 RESEARCH DESIGN AND METHOD 
 
The study was a mixed method study conducted based on both the quantitative and 
qualitative paradigms. A retrospective cohort study was conducted to review the DR-TB 
register for all DR-TB patients initiated on treatment during the time period January-
December 2013. A mixed method of both quantitative and qualitative paradigms, 
explorative and descriptive design was used and quantitative was utilized. For the 
purpose of the quantitative part of the study where documents and registers were 
analysed and the elements of the Health Belief Model were also used as a theoretical 
foundation.  
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1.12.1 Method 
 
The research methods as described by Pilot and Beck (2012:12) are techniques or 
procedures that researchers use for the structure and implementation of a study such 
as gathering and analysis of data relevant to the research question, problem statement 
and the study objectives. Therefore, in this section population, sample and sample 
technique, data collection process and analysis as well as measures to ensure validity 
and reliability, trustworthiness and ethical considerations were described. 
 
1.12.2 Population and sample selection 
 
Population refers to the entire group of persons or objects that is of interest to the 
researcher, in other words, that meets the criteria which the researcher is interested in 
studying (Brink, Van der Walt & Van Rensburg 2006:123). In this study population refers 
to all DR-TB patients on treatment in Swaziland.  
 
According to Polit and Beck (2008:338), the target population is the aggregate of cases 
about which the researcher would like to generalise the results or findings. The target 
population is formed by patients infected with DR-TB who are treated at the National 
Referral TB Hospital. A sample of informants was obtained from the accessible 
population. According to Brink et al (2006:123), an accessible population is the 
population that the researcher has access to and actually differs from the entire 
population in one or more aspects. Polit and Beck (2008:338) state that the accessible 
population is the aggregate of cases that conform to designate criteria and that are 
accessible as subjects for a study. In this study the accessible population were the DR-
TB patients who visited the health facility on the day of data collection.  
 
Within the accessible population the researcher considers the following inclusion and 
exclusion characteristics: 
 
Inclusion criteria 
 
Patients who are: 
 
• DR-TB Confirmed  
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• Initiated on DR-TB treatment during time period of study 
• >18 years old 
• Both males and females 
 
Exclusion criteria 
 
• <18 years 
• Drug resistant patients initiated before or after the study period 
 
1.12.3 Sample and sample techniques 
 
Following the mixed method approach, the researcher conducted both probability and 
nonprobability sampling methods. Nonprobability sampling means that not every 
element of the population has an opportunity for selection in the sample (Burns & Grove 
2009:744). Probability sampling in form of random sampling was used to randomly 
select the respondents from the DR-TB register as guided by Morgan (2008). 
Convenience sampling was be used to recruit informants for the in-depth individual 
interviews. 
 
1.12.4 Sample size 
 
The sample size in the qualitative study was not pre-determined as data was collected 
until saturation occurred. Saturation occurred by the 18th individual interview where the 
researcher noticed that similar information was being shared by the patients. Fifty six 
cases were randomly selected from the register for the quantitative aspect of document 
analysis.  
 
1.12.5 Data collection 
 
Data was collected through individual interviews through use of an interview guide. 
Document interview was conducted through use of a checklist as a data collection tool. 
The qualitative interviews were audio recorded and transcribed verbatim. 
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1.12 6 Data analysis 
 
Data analysis occurred simultaneously with data collection. The eight steps provided by 
Tesch (1990) in Creswell (2013:184-187) to analyse data were mainly utilised to do the 
analysis of the qualitative data. 
 
The quantitative data from the DR-TB register was analysed through document analysis 
using content analysis approach with consultation with the statistician. 
 
1.12.7 Validity  
 
The validity of the checklist tool was ensured through face, content validity and 
consultation with experts in the field. The tool was also pre-tested. 
 
1.13 MEASURES TO ENSURE TRUSTWORTHINESS 
 
Measures to ensure trustworthiness in qualitative research refer to the accuracy of the 
findings by employing certain procedures (Creswell 2013:250). The following measures 
were taken into account: confirmability, dependability, transferability and credibility 
(Brink et al 2006:118, 119). 
 
1.14 ETHICAL CONSIDERATIONS  
 
In this study considerations were taken to ensure protection of the rights of the research 
institution, of participants, and ensuring scientific integrity. The ethical protection of 
respondents was maintained throughout the study. 
 
Protecting the rights of the institution  
 
This research falls under the authority of the Department of Health Studies of UNISA, 
since it is conducted in order to obtain a Master’s degree in Public Health from this 
institute. Therefore, the researcher sought official ethical approval from the 
Department’s Research Ethics Committee (Annexure A). In addition ethical clearance 
by the Swaziland’s Health Research Committee was also sought for (Annexure A). 
Moreover this research took place under the authority of the management of National 
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DR-TB Referral Hospital. Therefore, after obtaining ethical approval of the Ethics 
Committee of the Department of Health Studies a letter of application for permission to 
conduct this research was requested and obtained from the National Tuberculosis 
Control Program and the management of the respective facility (Annexure B and C). 
 
1.15 SCIENTIFIC INTEGRITY OF THE RESEARCH 
 
The researcher adhered to the principles of scientific integrity by avoiding plagiarism. 
These included: honesty in reporting, referencing and communicating the findings. 
 
Privacy and confidentiality was maintained by keeping all data obtained under lock and 
key.  
 
Anonymity may be difficult to maintain but all measures to protect the participants were 
ensured. Participants were informed that they may withdraw from the study at any time 
without victimisation. 
 
Scientific integrity was ensured through avoiding plagiarism, acknowledging all sources 
used and writing the correct list of sources. 
 
1.16 DISSEMINATION OF FINDINGS 
 
The findings will be published in an accredited journal for wider readability; a poster will 
be developed and presented through in-service education to patients and staff. 
 
1.17 SCOPE AND LIMITATIONS OF THE STUDY 
 
The scope of this study was limited because of the small sample size of the qualitative 
part and it is not easy to generalise or transfer results to a wider community. Although 
some information will be obtained from the register it may have variables that are 
inaccurate or incomplete.  
 
1.18 ORGANISATION OF THE DISSERTATION 
 
The dissertation is divided in the following chapters. 
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Table 1.1:  Organisation of the dissertation 
 
Chapter Logic and structure of the thesis 
Chapter 1 Introduction and background information. 
 
This chapter introduced an overview and 
introduction on tuberculosis and MDR-TB; it briefly 
described the background of the research 
phenomena. 
Chapter 2 Literature review 
 
In this chapter the different scholarly articles on risk 
factors related to drug resistant TB were discussed 
in-depth. 
Chapter 3 Research methods and research design 
Chapter 4 Findings and literature control 
Chapter 5 Discussions of findings 
Chapter 6 Conclusions, limitations and recommendations. 
 
 
1.19 CONCLUSION 
 
Chapter 1 gives introductive information of the entire study which utilised a mixed 
method approach. In the chapter, the background information to the research problem 
that existed has been discussed and the purpose, research question and objectives 
have been outlined. The significance of the study and definition of key concepts have 
been presented. The research design and method have been outlined to indicate how 
the study was conducted, such as research context, population, sample and sampling 
method, data collection methods and analysis. Methods of how validity and reliability, 
and trustworthiness were ensured are outlined. Ethical consideration of the research 
has also been outlined. Scope and limitations of the study is introduced. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 INTRODUCTION 
 
A literature review provides you with the current theoretical and scientific knowledge 
about a particular problem, and resulting in a synthesis of what is known and unknown. 
Such reviews include:  a description of the current knowledge of a practice problem, the 
identification of the gaps in this knowledge base, and the contribution of the present 
study to the building of knowledge in this area (Burns & Grove 2007:135). 
 
In this chapter the literature review was conducted to contribute to already available 
current knowledge and information that could lead to a better understanding of risk 
factors that influence the epidemiology for consistency and the golden thread of DR-TB 
among patients.  
 
The primary rationale for reviewing literature relevant to this study was to gain an 
understanding of the information available on risk factors influencing the epidemiology 
of DR-TB on patients among patients that are already on DR-TB treatment. It was the 
researcher’s intent to determine whether there are certain risk factors that are more 
likely than others that have a direct link with the development of DR-TB amongst 
patients already on DR-TB treatment. For this purpose the researcher reviewed mostly 
international journal publications and sources from a number of data bases on risk 
factors, such as Google Scholar, eBooks and other relevant clinical online data bases. 
However, it was discovered that most of the scientific knowledge was done outside 
Africa, in places such as China, United States of America, India with a few studies 
conducted in South Africa and none in Swaziland. 
 
Many factors propagate the spread of drug-resistant TB, and lead to widespread 
emergence of XDR TB. These factors include:  
Diagnostic factors: lack of rapid, cheap, and accessible point-of-care diagnostic 
methods to rapidly diagnose drug-resistant TB as early as possible 
Limited drug regimen: insufficient second-line drug options 
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Patient treatment adherence and retention:  poor patient adherence to prolonged 
treatment; inadequate case holding; poor treatment strategies.  
Social issues: social stigma; deprivation and poverty; absence of community 
engagement. 
Political will: insufficient political support  
Equipment and supplies: inadequate resources for quality services. 
(Abubakar, Signol, Falson, Raviglione, Ditiu et al 2013:4) 
 
The complex interaction between the host and M TB, affected by concomitant infections 
and wider social determinants, compound these structural factors. The genetic makeup 
of some M TB strains could increase risk of drug resistance. In several countries, 
primary transmission of MDR and XDR TB have been well documented, and have 
drawn attention to the crucial need to implement infection control precautions in 
congregate settings, according to Abubakar, Signol, Falson, Raviglione, Ditiu et al 
(2013:4). Concurring to this construct Shenoi, Escombe and Friedland (2010:256) 
acknowledged that the dramatic occurrence of 2 seemingly unrelated events, finally 
brought the issue of transmission of drug-resistant TB,  its relationship to the HIV 
epidemic, and the global absence of adequate TB infection control into glaring public, 
medical, and scientific view.  
 
Therefore, the risk factors influencing DR-TB was explored as the context that shapes 
and influences the current disease DR-TB trends in Swaziland and the awareness of 
these will assist in the control of the disease transmission amongst the public. 
 
2.2 DRUG RESISTANT TB PATHWAYS 
 
According to the WHO (2015:1), the reasons why multidrug resistance continues to 
emerge and spread are mismanagement of TB treatment and person-to-person 
transmission. These two are shown below.  
 
  
  
23 
First Pathway:  Exposure to drug susceptible TB  
 
   Infection with drug susceptible TB  
  
   Active drug susceptible TB  
 
   Exposure to anti TB drugs 
 
Active drug resistant TB 
 
Second Pathway:  Exposure to drug resistant TB from Primary Source 
  
    Infection with drug resistant TB   
 
   Active drug resistant TB 
 
Understanding the pathway of how people are exposed to DR-TB will help clinicians to 
manage and treat the diseases effectively. 
 
2.3 GLOBAL DRUG RESISTANT TB PICTURE 
 
Globally TB is the second most common cause of death from infectious disease (after 
HIV). The absolute number of TB cases has been decreasing since 2005 and new 
cases since 2002. China has achieved particularly dramatic progress, with an 80 
percent decline in its TB mortality rate. The distribution of TB is not uniform across the 
globe; about 80% of the population in many Asian and African countries test positive in 
tuberculin tests, while only 5–10% of the US population test positive (Epidemiology of 
TB 2013:1). 
 
Generally the prevalence of both drug-susceptible (DS-TB) and DR-TB appeared to 
decrease again in industrialized countries and recede from public and professional 
interest as highly active antiretroviral therapy (HAART) became available and TB 
programs strengthened airborne infection control. In many resource-limited settings, 
however, particularly in Africa, Asia, and the countries of the former Soviet Union, rates 
of DS-TB and DR-TB continued to increase, and TB re-emerged as a serious global 
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public health threat. World Health Organization (WHO) surveillance revealed high and 
increasing rates of drug resistance in retreatment cases and, shockingly, also in new, 
previously untreated TB cases. More than half of the estimated 500,000 global MDR-TB 
cases diagnosed in 2007 were believed to have resulted from primary transmission of 
drug-resistant organisms (Abubakar, Signol, Falson, Raviglione, Ditiu et al (2013:4-12; 
Shenoi et al 2010:251).  
 
Roughly one-third of the world's population has been infected with M. TB, and new 
infections occur at a rate of one per second. However, not all infections with M. TB 
cause TB disease and many infections are asymptomatic. In 2007 there were an 
estimated 13.7 million chronic active cases, and in 2010 there were 8.8 million new 
cases, and 1.45 million deaths, mostly in developing countries. 0.35 Million of these 
deaths occur in those co-infected with HIV (Epidemiology of TB 2013:1). 
 
According to the WHO Report (2014:14), China, India and Soviet Union has over 50% 
of the DR-TB cases primarily due to the high population density of these countries. 
Globally the treatment success rate for DR-TB is 48%. In 2007, the country with the 
highest estimated incidence rate of TB was Swaziland, with 1 200 cases per 100 000 
people. As of 2014, India has the largest total incidence, with an estimated 2.2 million 
new cases. India has more than 0.3 million deaths and economic losses of $23 billion 
every year. TB caused the second highest number of deaths in India with 63 265 
casualties in 2011, 61887 in 2012 and 57 095 in 2013.  Shenoi et al (2010:251) state 
that the lack of treatment options could endanger already diminished resources for TB 
control and potentially result in another disastrous surge of both drug-resistant and 
drug-susceptible TB globally.  
 
In the United Kingdom, the national average was 15 per 100 000 in 2007, and the 
highest incidence rates in Western Europe were 30 per 100 000 in Portugal and Spain. 
These rates compared with 98 per 100 000 in China and 48 per 100 000 in Brazil. In the 
United States, the overall TB case rate was 4 per 100 000 persons in 2007. In Canada, 
TB is still endemic in some rural areas. Generally in developed countries, TB is less 
common and is mainly an urban disease.   
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2.4 SUB-SAHARAN AFRICA DR-TB PICTURE 
 
A 2010 report by the WHO reported on new cases of XDR-TB, defined as MDR-TB plus 
resistance to any fluoroquinolone and any of the injectable second-line agents found in 
the region at KwaZulu-Natal Province, South Africa. This discovery called for attention 
to the dangers of nosocomial TB transmission in the presence of HIV infection and 
AIDS and the consequences of limited or no attention to infection control. XDR-TB was 
reported in 53 patients from a setting with a high prevalence of TB and HIV infection 
and a hospital with large congregate TB wards similar to those in most resource- limited 
settings. Reminiscent of the earlier outbreaks, all patients tested were HIV infected, and 
there was almost complete and rapid mortality. Nosocomial transmission was apparent 
because most patients had not previously been treated for TB and two-thirds had been 
hospitalised in the preceding 2 years. In addition, 85% of tested XDR Mycobacterium 
TB isolates were of a similar genetic family, and several HCWs were among the 
persons who were infected and died. (Ghandi et al 2006:24) 
 
To support these findings where DR-TB was linked to HIV, Gandhi, Moll, Sturm, 
Pawinski, Govender, Lalloo, Zeller, Andrews and Friedland (2006:1) state that the 
number of TB cases in sub Saharan Africa has increased substantially in the past 
decade, fueled by the HIV epidemic, making it difficult for TB programmes to improve 
outcomes. In South Africa, the national DOTS treatment success rate has been 
reported to be only 67%, well below the WHO standard of 85%. Low rates of treatment 
completion place patients at risk for relapse of TB disease as well as for development of 
drug resistance. The incidence of TB varies with age. In Africa, TB primarily affects 
adolescents and young adults who happen to be also the highly infected with HIV. 
 
2.5 SWAZILAND DR-TB PICTURE 
 
In 2007, the country with the highest estimated incidence rate of TB was Swaziland, 
with 1 200 cases per 100 000 people. The TB/HIV co-infection rate in the country 
remains high at 79.6%. The country due to the high TB incidence then declared TB as a 
national emergence. The country has been faced with various issues related to DR-TB 
such as: 
 
• Inadequate follow up and support mechanisms for patients on MDR-TB treatment  
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• Inadequate contact tracing mechanisms for contacts of MDRTB patients 
• Lack of capacity (human resource capacity)  
• Human resource: Numbers and skills and knowledge on XDRTB  
• No operational surveillance system in place 
• Pill burden creates high default rates and increase occurrence of side effects  
• Referral system between the two programmes is weak (collaborative TB/HIV at 
facility level still a challenge)  
• Health workers not utilizing IPC protective supplies such as N95  
 
In response to these issues a number of targeted efforts were implemented including 
Conducting a rapid survey of drug-resistant TB to establish whether Swaziland has 
cases of Extreme Multi drug Resistant TB. The health workers to manage DR-TB at 
national level including clinicians, nurses and TB programme staff to effectively respond 
to M(X) DR-TB have been regularly capacitated. Strengthening and expanding current 
national TB laboratory capacity to deal with diagnosis for drug resistant TB through fast 
diagnostic measures such as GeneXpert and the development of comprehensive DR-
TB guidelines that incorporate collaborative TB/HIV activities. 
 
To declaration of tuberculosis a national disaster has aided in the positive direction in 
TB management. 
 
According to Abubakar et al (2013:3), factors driving MDR and XDR TB arise because 
of inadequate or interrupted administration of first line treatment. If patients are given 
too few drugs, for too short a period, or drugs to which the infecting strain is partly 
resistant, the resistant strains are favoured and will eventually dominate in the body. 
However once the drug resistant strains have been selected and occur in a community, 
they are directly transmitted to others. This cycle shows the first pathway caused by 
exposure to anti TB drugs that eventually leads to the second pathway where there is 
direct infection with drug resistant TB. 
 
According to Espinal, Laserson, Camacho, Fusheng, Kim, Tlali et al (2001:1) prior but 
ineffective treatment is a strong predictor of drug resistance, and that HIV is not an 
independent risk factor for MDR-TB. The association between length of treatment and 
drug resistance may reflect longer treatment as a result of treatment failure in patients 
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with drug resistance; it may also reflect irregular prior treatment for TB, leading to drug 
resistance. 
 
WHO (2015:1) recommend these solutions to control drug-resistant TB: 
 
• Cure the TB patient the first time around. 
• Provide access to diagnosis. 
• Ensure adequate infection control in facilities where patients are treated 
• Ensure the appropriate use of recommended second-line drugs. 
 
In 2014, an estimated 480 000 people worldwide developed MDR-TB. It is estimated 
that about 9.7% of these cases were XDR-TB. 
 
2.6 RISK FACTORS FOR TB AND DR-TB 
 
TB drug resistance is said to be present if growth of M. TB isolates is observed in spite 
of the presence of anti-TB drugs. Although its causes could be microbial, clinical or 
programmatic, DR-TB is essentially a man-made phenomenon. From a microbiological 
perspective, resistance is caused by a genetic mutation that makes a drug ineffective 
against the mutant bacilli. From a clinical and programmatic perspective, it is an 
inadequate or poorly administered treatment regimen that allows a drug-resistant strain 
to become the dominant strain in a patient infected with TB.  
 
Short-course chemotherapy (SCC) for patients infected with drug-resistant strains may 
create even more resistance to the drugs in use. This has been termed the “amplifier 
effect” of SCC. Ongoing transmission of established drug-resistant strains in a 
population is also a significant source of new DR cases. Swaziland Drug Resistant TB 
Manual (2014:18). 
 
2.6.1 Institutional related risk factors  
 
These factors result in inadequate treatment regimens, it basically refers to those 
factors that the health care worker has direct influence over, resulting in inadequacy of 
the drug regimens. These factors include the following: 
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Inappropriate guidelines or noncompliance with guidelines 
 
The WHO (2010:3) states that the mainstay of TB control is organising and 
administering standardised treatment across the country for all adult and paediatric TB 
cases on aspects such as sputum smear-positive or smear-negative. For 
standardisation the WHO recommends the adoption of its guideline on patient 
categorisation and management to be followed. These guidelines emphasise use of the 
most effective standardised, short-course regimens, and of fixed-dose drug 
combinations (FDCs) to facilitate adherence to treatment and to reduce the risk of the 
development of drug resistance. 
 
Absence of guidelines 
 
Absence of guidelines or in-availability of guidelines in health facilities to provide 
reference for the health care worker may result in health care workers providing 
different treatments as there is no guide.  
 
Poor training 
 
Poor training will result in poor knowledge transfer to the health care worker on the 
implementation ground. The health care worker may also lack confidence in following 
the set standards as she may lack proper training. The case may be the same in all the 
hospital departments even in the laboratories. According to WHO a wide network of 
properly equipped laboratories with trained personnel is necessary to ensure access to 
quality-assured sputum smear microscopy for early detection, initiation of TB treatment 
and prevention of DR-TB.  
 
Poor monitoring of treatment 
 
TB and DR-TB like all other health ailments require constant monitoring of progress. In 
DR-TB and TB the dosages of the medications are based on the weight of the patient. 
When a patient’s weight increases the dosage should also increase once the monitoring 
of such determinants is poor the patient will end up with low dosage resulting in 
resistance. 
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The WHO (2010:2) recommended method of TB case detection, first using sputum 
smear microscopy and then culture and drug susceptibility testing (DST), as indicated 
below. Strengthened laboratory network.  
 
Poorly organised or funded TB control programmes 
 
The TB Control Program is the backbone of every country’s health prevention and 
control of the TB disease. If the program is poorly organised or lacks funding it cannot 
function optimally as most activities and intervention cannot take off due to lack of funds 
or proper coordination. 
 
Drugs: Inadequate supply or regimen 
 
According to WHO (2010:3), an uninterrupted and sustained supply of quality-assured 
anti-TB drugs is fundamental to TB control. For this purpose, an effective drug supply 
and management system is essential. A reliable system of procurement and distribution 
of all essential anti-TB drugs to all relevant health facilities should be in place. The TB 
recording and reporting system is designed to provide the information needed to plan, 
procure, distribute and maintain adequate stocks of drugs. 
 
Anti-TB drugs should be available free of charge to all TB patients, both because many 
patients are poor and may find them difficult to afford, and because treatment has 
benefits that extend to society as a whole (cure prevents transmission to others). 
Legislation related to drug regulation should be in place, and use of anti-TB drugs by all 
providers should be strictly monitored. The use of FDCs of proven bioavailability and of 
innovative packaging such as patient kits can help to improve drug supply logistics as 
well as drug administration, promote adherence to treatment and prevent development 
of drug resistance. 
 
Poor quality 
 
This is a result of governments purchasing drugs that are not accredited, favouring 
costs to quality. In the long run this can cost the very government that was maximising 
its purchasing power. 
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Unavailability of certain drugs (stock-outs or delivery disruptions) 
 
This can be a result of poor forecasting by the supply chain experts. It may start from 
implementation level where the health care worker fails to account for the drugs used 
and constantly have stock outs resulting in patients’ treatment being interrupted. 
 
Poor storage conditions 
 
Poor storage conditions result in drugs losing their potency and as a result drugs with 
poor potency will be given to the unsuspecting patient. Poor storage conditions include 
too much sunlight, warmth, placing of drugs on the floor, storing drugs without following 
a system to assist in using the drugs that were received first. 
  
Wrong dose or combination of drugs 
 
Wrong doses can be given to patients during their refills due to not following the weight 
dosage standards and wrong combination of the drugs can be another factor. 
 
2.6.2 Patient factors 
 
These factors result in inadequate drug intake by the patient. Poor adherence (or poor 
DOT): DOTS is defined as directly observed treatment, short-course, and is the name 
given to the TB control strategy recommended by the World Health Organisation. 
According to the (WHO 2008:53), “the most cost-effective way to stop the spread of TB 
in communities with a high incidence is by curing it. 
 
Identifying and addressing patient factors such as physical, financial, social and cultural 
barriers and the health care workers as well as health system-barriers to accessing TB 
treatment services should be done. Particular attention should be given to the poorest 
and most vulnerable population groups. Examples of actions that may be appropriate 
include expanding treatment outlets in the poorest rural and urban settings, involving 
providers who practise close to where patients live, ensuring that services are free or 
heavily subsidised, offering psychological and legal support, addressing gender issues, 
improving staff attitudes, and undertaking advocacy and communication activities (WHO 
2010:5). 
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Adverse effects of treatment and lack of information on treatment 
 
The main objectives of TB therapy are to cure the patients and to minimise the 
possibility of transmission of the bacillus to healthy subjects. Adverse effects of anti-TB 
drugs or drug interactions (among anti-TB drugs or between anti-TB drugs and other 
drugs) can make it necessary to modify or discontinue treatment. The major side effects 
from TB include psychosis, convulsive seizures, mental confusion, and coma: 
Peripheral neuropathy: Peripheral neuropathy occurs in approximately 20% of patients 
on TB treatment, Clinical hepatitis: Hepatotoxicity: Transitory and asymptomatic 
increases in the serum levels of bilirubin and hepatic enzymes occur in 5% of patients. 
These reactions can lead patients to interrupt or abandon treatment, resulting in higher 
rates of treatment failure and acquired resistance, as well as an increase in the number 
of TB cases and, more rarely, in the number deaths (Arbex, Varella, Siqueira & Fiúsa de 
Mello 2010:627). With development of these side effects and lack of proper information 
to the patient the patient may decide to stop treatment on her own.  
 
Although the therapeutic regimens are extremely effective, studies have shown that 
undesirable drug interactions (among the anti-TB drugs or between the anti-TB drugs 
and other drugs used by patients) can occur, as can adverse reactions of varying 
degrees of severity. Adverse reactions that are more severe contribute to changes in 
the therapeutic regimen and lead to the use of drugs that are less active and 
occasionally more toxic, substantially increasing treatment costs, as well as the number 
of home visits, outpatient visits, and hospitalisations. These reactions can lead patients 
to interrupt or abandon treatment, resulting in higher rates of treatment failure and 
acquired resistance, as well as an increase in the number of TB cases and, more rarely, 
in the number of deaths.  
 
2.6.3 Social barriers 
 
The institutional and community norms that lead to the stigmatization of TB are thought 
to hinder TB control. Several themes emerged: fear of infection is the most common 
cause of TB stigma; TB stigma has serious socioeconomic consequences, particularly 
for women; TB stigma is perceived to increase TB diagnostic delay and treatment 
noncompliance, although attempts to quantify its impact have produced mixed results; 
and interventions exist that may reduce TB stigma (Courtwright & Turner 2010:125). 
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Mental disorder 
 
TB and mental illness share common risk factors including homelessness, HIV positive 
serology, alcohol/substance abuse and migrant status leading to frequent comorbidity. 
Rates of mental illness of up to 70% have been identified in TB patients. Medications 
used in the treatment of common mental illnesses, such as depression, may have 
significant interactions with anti-TB agents, especially isoniazid and increasingly 
linezolid. Many medications used in the treatment of TB can have significant adverse 
psychiatric effects and some medications such as rifampicin may reduce the effective 
doses of anti-psychotics y their enzyme induction actions. Treatment with agents such 
as cycloserine has been associated with depression, and there have been reported 
cases of psychosis with most anti-tuberculous agents. Mental illness and substance 
abuse may also affect compliance with treatment, with attendant public health concerns. 
(Doherty, Kelly, McDonald, O'Dywer, Keane & Cooney 2013:396). 
 
Poverty and stigma 
 
Tuberculosis can drive entire countries, not just the people within them, into ever deeper 
poverty. It is no coincidence that the countries with the highest rates of TB are also 
some of the poorest and/or most unequal societies. TB is more common in countries 
where many people live in absolute poverty because people are more likely to: 
 
• live and work in poorly ventilated and overcrowded conditions, which provide 
ideal conditions for TB bacteria to spread 
• suffer from malnutrition and disease – particularly HIV – which reduces 
resistance to TB 
• have limited access to healthcare – and just one person with untreated infectious 
TB can pass the illness on to 10-15 people annually 
 
TB affects the vulnerable 
 
In any society, rich or poor, TB tends to impact heavily on the poorest and most 
marginalised groups:  
 
  
  
33 
• Migrant communities 
• People with drink, drug or mental health issues 
• Homeless people and those in poor quality housing 
• People with weak immune systems, due to HIV, other illnesses or age 
• People with a history of prison 
 
People with TB can find themselves in a downward spiral of poverty. This is because: 
They are often unable to work or attend school – for 3-4 months on average. Carers, if 
needed, may be expected to give up work or school themselves. This can result in a 
significant loss of earnings and/or reduce a child’s future earning potential. If a patient 
dies, a family loses about 15 years of potential income. People may not be aware of, or 
able to access, free treatment and may end up paying traditional healers or private 
doctors. Even where TB treatment and drugs are free there is often a cost of travelling 
to clinics and additional heating or nutrition needs. 
 
People can lose their jobs, or be excluded from future employment, because of fears 
surrounding TB. Women may be divorced, or considered unworthy of marriage, if they 
are known to have been affected by TB, making them more likely to experience extreme 
poverty. 
 
2.6.4 The 5 elements of DOTS  
 
These five elements are the basics needed for the control of TB as recommended by 
the WHO Stop TB Strategy. 
 
Political commitment with increased and sustained financing 
 
Clear and sustained political commitment by national governments is crucial if basic 
DOTS and the Stop TB Strategy are to be effectively implemented. Political commitment 
is needed to foster national and international partnerships, which should be linked to 
long-term strategic action plans prepared by NTPs. Strategic action plans should 
address technical and financial requirements and promote accountability for results at 
all levels of the health system, political commitment should be backed up by national 
legislation. 
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The WHO acknowledged that currently resources are inadequate, and there was need 
to urgently mobilise additional resources from within the country, as well as international 
sources. The global financing and partnership resources now available for poverty 
reduction, health systems improvement and disease control offer new opportunities for 
TB control programmes. Even with adequate financing, critical deficiencies in human 
resources in the health sector will impede progress in many low- and middle-income 
countries, especially in Africa (WHO 2010:1). 
 
Case detection through quality-assured bacteriology 
 
Culture and DST services should be introduced, in a phased manner, at appropriate 
referral levels of the health system. Their functions should include diagnosis of sputum 
smear-negative TB, diagnosis of TB among HIV-positive adults and children, diagnosis 
and monitoring of response to treatment of MDR-TB, and testing related to periodic 
surveys of the prevalence of drug resistance. Maintaining the quality of the laboratory 
network depends on regular training, supervision and support, and motivation of 
laboratory staff. Best use should be made of existing public and private laboratories. 
 
Standardised treatment, with supervision and patient support 
 
Treatment services 
 
The mainstay of TB control is organising and administering standardised treatment 
across the country for all adult and paediatric TB cases – sputum smear-positive, 
smear-negative, and extra pulmonary. For standardisation the WHO recommends the 
adoption of its guideline on patient categorisation and management to be followed. 
These guidelines emphasise use of the most effective standardised, short-course 
regimens, and of fixed-dose drug combinations (FDCs) to facilitate adherence to 
treatment and to reduce the risk of the development of drug resistance. 
 
Supervision and patient support 
 
According to WHO factors resulting in patients interrupting or stopping treatment should 
be identified and addressed. Supervised treatment, which may have to include direct 
observation of therapy (DOT), helps patients to take their drugs regularly and complete 
  
35 
treatment, thus achieving cure and preventing the development of drug resistance 
(WHO 2010:3). 
 
Supervision must be carried out in a context-specific and patient-sensitive manner, and 
is meant to ensure adherence on the part both of providers (in giving proper care and 
support) and of patients (in taking regular treatment). Treatment monitoring can be at a 
health facility, workplace, in the community or at home. It should be provided by a 
treatment supporter who is acceptable to the patient and is trained and supervised by 
health services. Patient and peer support groups can help to promote adherence to 
treatment. 
 
Improving access to treatment 
 
An effective drug supply and management system 
 
An uninterrupted and sustained supply of quality-assured anti-TB drugs is fundamental 
to TB control. For this purpose, an effective drug supply and management system is 
essential. The Global Drug Facility and the Green Light Committee offer countries with 
limited capacity the benefit of access to quality-assured TB drugs at reduced prices and 
also facilitate access to training on drug management. 
 
Monitoring and evaluation system, and impact measurement 
 
Recording and reporting system 
 
Establishing a reliable monitoring and evaluation system with regular communication 
between the central and peripheral levels of the health system is vital. This requires 
standardised recording of individual patient data, including information on treatment 
outcomes, which are then used to compile quarterly treatment outcomes in cohorts of 
patients. These data, when compiled and analysed, can be used at the facility level to 
monitor treatment outcomes, at the district level to identify local problems as they arise, 
at provincial or national level to ensure consistently high-quality TB control across 
geographical areas, and nationally and internationally to evaluate the performance of 
each country. Regular programme supervision should be carried out to verify the quality 
of information and to address performance problems. 
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Making the best use of data at all levels will mean many countries having to train staff in 
the analysis and interpretation of data, as well as in the use of the computer software 
that can greatly facilitate this work. As electronic recording systems become more 
widely available, consideration should be given to storing individual patient data, which 
will make more detailed analyses of aggregated data possible. 
 
2.7 THEORETICAL FOUNDATION 
 
The Health Belief Model (HBM) is by far the most commonly used theory in health 
education and health promotion (Glans, Rimer & Lewis 2002). It was developed in the 
1950’s as a way to explain why medical screening programs offered by the United 
States Public health service, particularly for TB, were not very successful (Hochbaum 
1958). The underlying concept of the original HBM is that behaviour is determined by 
personal beliefs or perceptions about a disease and the strategies available to decrease 
its occurrence (Hochbaum 1958). 
 
There are four perceptions that serve as the main constructs of the model: perceived 
seriousness, perceived susceptibility, perceived benefits, and perceived barriers. Each 
of these perceptions, either individually or in combination can be used to explain health 
behaviour. Recently, some other constructs have been added to the HBM; the model 
has therefore been expanded to include cues to action, motivating factors and self-
efficacy as exhibited in figure 2.1. 
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Figure 2.1   Health Belief Model 
(Adapted from:  Hayden, Hollmeyer, Poland & Buchholz 2009:34) 
 
The model includes three constructs that ought to be combined to predict health-related 
behaviours, as applied in the context of the study. These are the individual perception, 
modifying factors and likelihood of action. 
 
Individual perception 
 
Individual perceptions refer to the way in which TB patients may reflect valuing their 
health, when compared to the other aspects of life. These perceptions include the 
following variables: 
 
  
Individual 
perception 
Modifying 
factors 
Likelihood of 
action 
Age 
Sex 
Ethnicity 
Personality 
Perceived 
Benefits 
Minus 
Perceived 
Threat 
Likelihood of 
behaviour Perceived 
Susceptibility/ 
Perceived 
Cues to 
action 
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Perceived seriousness 
 
This construct speaks to an individual’s belief about the seriousness or severity of a 
disease. This is often based on medical information or knowledge but may also come 
from the beliefs a person has about the difficulties a disease would create or the effects 
it would have on his or her life in general (Hayden et al 2009:31). 
 
Perceived susceptibility 
 
Personal risk or susceptibility is one of the more powerful perceptions in prompting 
people to adopt healthier behaviours. The greater the perceived risk, the greater the 
likelihood of engaging in behaviours to decrease the risk. This is what prompts 
homosexual men to be vaccinated against hepatitis B (De Wit et al 2005) and to use 
condoms in an effort to decrease susceptibility to HIV infection (Belcher et al 2005). 
When the perception of susceptibility is combined with seriousness, it results in 
perceived threat (Stretcher & Rosenstock 1997). If the perception of threat is to a 
serious disease for which there is a real risk, behaviour often changes. 
 
Modifying factors 
 
The four constructs described above are modified by other variables such as culture, 
past experience, educational level, skill, motivation etc. These are individual 
characteristics that influence personal perceptions. For example, if one is diagnosed 
with breast cancer and successfully treated, she may have a heightened perception of 
susceptibility because of this past experience and be more conscious of breast self-
examination because of past experience. Conversely, this past experience could 
diminish the person’s perception of seriousness because the cancer was easily treated 
and cured (Hayden et al 2009:33). 
 
Cues to action 
 
In addition to the four perceptions and modifying variables, the HBM suggests that 
behaviour is also influenced by cues to action. Cues to action are events, people or 
things that move people to change their behaviour e.g. illness of a family member 
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(Graham 2002), advice from others or reminder post cards from health care provider (Ali 
2002). 
 
Likelihood to take action 
 
According to the HBM, modifying variables, cues to action and self-efficacy affect 
people’s perception of susceptibility, seriousness, benefits and barriers and therefore 
own behaviour (see figure 2.1). 
 
Likelihood to take action is influenced by perceptions of the benefits of the action to be 
taken if dealing with risk factors about DR-TB infection is perceived to have been able to 
make a difference in their quality of life, as well as in reducing high mortality rates 
amongst them.  
 
Perceived benefits 
 
This is a person’s opinion of the value or usefulness of a new behaviour in decreasing 
the risk of developing a disease. People tend to adopt healthier behaviours when they 
believe the new behaviour will decrease their chances of developing a disease (Hayden 
et al 2009:32). 
 
Perceived barriers 
 
This is a person’s evaluation of the obstacles in the way of him or her adopting a new 
behaviour. Of all the constructs, perceived barriers are the most significant in 
determining behaviour change (Janz & Becker 1984). In order for a new behaviour to be 
adopted, a person needs to believe the benefits of the new behaviour outweigh the 
consequences of continuing the old behaviour (Center of Disease Control and 
Prevention 2004). This enables barriers to be overcome and the new behaviour to be 
adopted. 
 
Self-efficacy 
 
Self-efficacy was added to the original 4 beliefs of the HBM in 1988 (Rosenstock, 
Stretcher & Becker 1988). It is the belief in one’s own ability to do something (Bandura 
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1977). People generally do not try to do something new unless they think they can do it. 
If someone believes a new behaviour is useful (perceived benefit), but does not think he 
or she is capable of doing it (perceived barrier), chances are that it will not be tried 
(Hayden et al 2009:31). 
 
This model adapted from the behavioural sciences (Stretcher & Rosenstock 1997) is 
one of the most widely recognised frameworks of health behaviour and may be applied 
to health- seeking behaviour for glaucoma. The model explains how a person perceives 
the threat of glaucoma, and consequent loss of vision from glaucoma, and how the 
need for early consultation is viewed. The three constructs of the model are individual 
perceptions about susceptibility to disease, modifying factors and variables affecting the 
likelihood that a person will take action to change behaviour based on perceived 
benefits and barriers. 
 
2.8 CONCLUSION 
 
This chapter has discussed the literature review conducted for the study. Varied   
literature was consulted, which covered different topics, such as the DR pathways, the 
picture of risk factors related to DR-TB globally, at Sub-Saharan, and in Swaziland, The 
HBM, which was the conceptual framework of the study, was highlighted and developed 
to act as a guide for the study especially in data collection and analysis. 
 
Chapter 3 discusses the research design and method. 
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CHAPTER 3 
 
RESEARCH METHODOLOGY 
 
 
3.1 INTRODUCTION 
 
The research methodology is the study of the theoretical, philosophical and 
epistemological assumptions as well as the social processes through which research is 
conducted (Powers & Knapp 2006:112-113; Rapport 2004:166). It has philosophical 
meaning and typically refers to the approach or the paradigm that forms the basis of the 
research (Blaxter, Hughes & Tight 2010:59) which is most commonly based on the 
quantitative or qualitative approaches. In this study the research methodology refers to 
the context of the study, research design and research method. However, the research 
objectives, question and hypothesis are discussed first. 
 
3.2 OBJECTIVES OF THE STUDY: 
 
The objectives of this study were to 
 
• explore and describe the risk factors influencing the epidemiology of DR-TB 
amongst patients enrolled on DR-TB 
• Identify risk factors influencing the epidemiology of DR-TB amongst patients 
enrolled on DR-TB treatment 
• Develop a poster that will exhibit the research process undertaken and the 
findings 
 
 3.3 RESEARCH QUESTION 
 
The research question of this study was formulated based on the PICO approach. The 
acronym stands for the following: 
 
• P − Population which in this study is the DR-TB Patients who are enrolled for the 
DR-TB treatment. 
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• I − Intervention which is the reduction of risk factors predisposing patients to DR-
TB. 
• C − Comparison with global incidences and prevalence of DR-TB. 
• O − Outcomes reduced transmission of DR-TB. 
 
Therefore, the research question for this study was: 
 
“What are the risk factors that influence DR-TB occurrence among patients enrolled on 
DR-TB treatment?” 
 
3.4 HYPOTHESIS OF THE STUDY 
 
A research hypothesis (H1 or Ha) is the alternative to the null and is according to Creswell 
(2013:143), the prediction that a researcher makes about the expected outcomes of the 
relationship among study variables. These hypotheses are numeric estimates of the 
values within populations which are based on the data collected from the given 
samples. Testing of hypotheses employs statistical procedures in which the researcher 
draws inferences about the population which is used in the study sample (Creswell 
2013:143). 
 
Hypothesis is defined as the formal statement of the expected relationship between two 
or more variables in a specified population (Burns & Grove 2007:542). 
 
LoBiondo-Wood and Haber (2010:39) define a hypothesis as a statement which 
involves the relationship between two or more variables that suggests an answer to the 
research question. The hypothesis is a declarative statement that predicts an expected 
outcome of a particular study. A hypothesis or hypotheses are formulated before a 
study is commenced as they provide the direction for the collection of data, the analysis 
and the interpretation of data. 
 
Hypotheses, which identify different types of relationships and the number of variables 
in a particular study, are divided into four categories namely: 
 
• Associative versus causal hypothesis. An associative hypothesis identifies 
variables that occur and exist together in a study, as one variable changes so 
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does the other. A causal hypothesis identifies a cause-and effect interaction 
among two or more variables, called independent and dependent variables 
(Burns & Grove 2009:171). Simple versus complex hypothesis.  A simple 
hypothesis predicts the type of relationship that will occur between two variables. 
Complex hypotheses predict the relationship between three or more variables 
(Burns & Grove 2009:172). 
• Non-directional versus directional hypothèses.  A null directional hypothesis 
states there is an existence of a relationship between variables, but cannot 
predict the nature of the relationship. A directional hypothesis does state the 
nature of the relationship between two or more variables (Burns & Grove 
2009:173). 
• Null versus research hypothesis. The null hypothesis which is also called the 
statistical hypothesis is utilised for statistical testing and interpretation of 
statistical outcomes. The research hypothesis is an alternative to the null 
hypothesis, and predicts a relationship between two or more variables. A null 
hypothesis can be simple or complex as well associative or causal. An 
associative null hypothesis states that there is no relationship between the 
variable of the study. A casual null hypothesis may be stated as there being no 
effect of the independent variable on the dependent variable (Burns & Grove 
2009:173-174).  
 
The independent variable with regards to this study is the DR-TB among patients. The 
dependent variable is the reduction of the occurrence of risk factors leading to DR-TB 
development (Creswell 2013:144). A hypothesis may therefore be formulated: There will 
be a simple causal relationship between the independent and independent variable with 
regards to this study. If the level of awareness regarding risk factors influencing DR-TB 
among patients is increased, it will influence programmatic interventions and in turn 
decrease the development of DR-TB. 
 
There will be a directional hypothesis between the dependent and dependent variable of 
this study. The researcher will be able to predict the direction of the relationship. The 
increase of awareness of DR-TB risk factors and putting in place targeted interventions 
will decrease the occurrence of DR-TB and reduce the incidence and prevalence of DR-
TB. 
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DEVELOPMENT OF DR-TB 
 
INTERVENTIONS THAT ARE 
EVIDENCE-BASED 
A null hypothesis of this study may be that there will be no association between the 
independent and dependent variables. That there will be no increased awareness of risk 
factors influencing DR-TB, no interventions put in place and no reduction of DR-TB 
Research hypothesis on figure 3.1 
 
 
  
 
 
 
 
 
 
 
Figure 3.1 Research hypothesis 
 
 
The research hypothesis of this study as exhibited in Figure 3.1 is that ‘There are 
increased high risk factors influencing development of DR-TB among patients enrolled 
on DR-TB than among those with susceptible TB. 
 
3.5 RESEARCH CONTEXT/SETTING 
 
The research setting is the specific place where the research study is conducted 
whereas the site is the overall location of the research context (Polit & Beck 2012:62). 
The research setting for this study is one of the hospitals in Manzini Swaziland. The 
Manzini region is the most densely populated region in the country with an average of 
+- 350,000 people. There are about 250 health facilities in the country that identify, 
diagnose and refer patients for treatment. However, there are seven DR-TB initiating 
sites that offer DR-TB treatment to patients diagnosed with DR-TB. However, this study 
was conducted at one of these sites which are a central DR-TB site where complicated 
and difficult cases are referred to. All facilities refer DR-TB patients diagnosed in their 
catchment area with the exception of the other DR-TB treatment initiating sites.  
 
 
HIGH RISK FACTORS 
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This facility serves a population of 1,018,449 but mainly 809,995 from the 3 regions 
Manzini, Hhohho, Lubombo.  It has been for a long time been the central treatment site 
for DR-TB until recently in 2010 when decentralisation was done to other facilities 
(shown in the map). Shiselweni the remaining region has a total of 3 DR-TB sites which 
caters for its own population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 TB patient populations by region 
(Source: National Strategic Plan 2014) 
 
It is a facility that initiates and provides monthly reviews and follow-ups of DR-TB 
patients. It has a turnover of about 30 patients daily, with an admission capacity of 100 
inpatients and also caters for ambulant patients who are initiated on DR-TB treatment, 
monitored monthly and given monthly refills by the medical officer. Those patients that 
require hospitalisation are also admitted at the same outpatient department. 
 
The facility out patient load, on a monthly basis on average there is patient load of 525-
600 (6600 visits per year), giving out a nurse-patient ratio of 1:13 monthly and the 
medical officer-patient ratio of 1:120. The services in this facility are available 24 hours 
a day, 7 days a week.  The staff members are exhibited on table 3.1. 
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Table 3.1 Staffing at the hospital 
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The picture of staffing at the study context is further well clarified on figure 3.3. 
 
 
Figure 3.3   Staffing at the hospital 
 
The staff compliment at the facility as exhibited in table 3.1 and figure 3.3 is reflected as 
5 Doctors, 2 Matrons, 6 Professional nurses, 48 Nurses of other categories, 2 
radiographers, 2 Lab technologists, 3 Micro-scopists, 1 Pharmacist, 2 Pharmacy techs, 
2 Data clerks, (1 IT personnel), 1 Audiologist (refer to table 3.1) The majority of the 
personnel in the facility are the nurses. 
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The services offered by the hospital in view of the study context include: 
 
• Out-patient services  
• Health Education on MDR-TB, TB/HIV co-infection 
• Screening for DR-TB and HIV  
• Provision of DR-TB treatment initiation and follow-up  
• Management of TB drug side effects  
• Provision of DOTS plus where a treatment supporter is linked to the patient for 
treatment monitoring throughout the treatment duration 
• In-patient admission services  
• Initiation and provision of ART to DR-TB patients  
• DR-TB treatment program through data management 
• Community DR-TB services, home assessment, mapping, screening of DR-TB 
contacts, tracing of DR-TB treatment defaulters 
• Audiology services  
• Physiotherapy and occupational therapy 
 
A research design appropriate to address the research problem is presented. 
 
3.6 RESEARCH DESIGN 
 
According to Polit and Beck (2008:766, 757), research design is a plan or a blue print of 
how you intend conducting the research, it focuses on the end product: what kind of a 
study is being planned and what kind of result is being aimed. The implementation of a 
good research study requires a clear research design to guide the data collection and 
analysis (Streubert & Carpenter 2011:33). In this study, a qualitative, quantitative, 
explorative and descriptive design was used.  
 
3.6.1 Qualitative 
 
Qualitative research is a systematic, interactive, subjective approach used to describe 
people’s life experiences and give them meaning. It is conducted to describe and 
promote understanding of human experiences such as pain, caring and comfort (Burns 
& Grove 2007:22). Creswell (2011:34) describes qualitative research as “an inquiry 
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process of understanding human experiences based on a distinct methodological 
tradition of inquiry that explores a social or human problem”. Qualitative research 
involves looking at characteristics or qualities that cannot easily be reduced to 
numerical values (Leedy & Ormrod 2010:94). 
 
Qualitative research is a way of gaining insight through discovering meanings. In 
qualitative studies, researchers begin by talking with or observing people who have first-
hand experience of the phenomenon under study (Polit & Beck 2012:532). This 
approach results in information that has the potential to elucidate varied dimensions of 
complicated phenomena, including caring for patients with TB or DR-TB. The 
researcher selected a qualitative design in order to investigate the experiences of DR-
TB patients enrolled on treatment concerning risks they are exposed to. 
 
In this study, a qualitative approach had the following advantages: 
  
• Qualitative methods are useful for exploring the full nature of a little understood 
phenomenon (Polit & Beck 2012:20).  
• Qualitative methods enable researchers to search for explanations about how or 
why a phenomenon exists or what a phenomenon means as a basis for 
developing a substantive theory that is grounded in rich, in-depth, experiential 
and empirical evidence. This mode of enquiry aims to examine the nuances and 
complexities of a particular phenomenon (Leedy & Ormrod 2010:94). 
• The kind of data obtained and the people selected as participants become 
focused and purposeful as the conceptualisation is developed and refined (Polit 
& Beck 2008:70).  The focus of qualitative research is usually broad and the 
intent is to give meaning to the whole as the qualitative researcher has an active 
part in the study (Burns & Grove 2007:23).  
• The participants who participated in this study were knowledgeable informants on 
the subject of being sufferers of the DR-TB disease.  
 
This approach assisted the researcher to construct representations based on the 
participants’ detailed knowledge and experiences about the condition (Polit & Beck 
2008:70). Furthermore, the design was suitable for gaining insight on what reality they 
attach to their world. 
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Quantitative 
 
A quantitative approach had the following advantages: 
 
• A scientific method, with a set of orderly, systematic, disciplined procedures were 
used to acquire information, in which the researcher progressed logically to 
access the data collecting documents, according to a specified plan of action and 
rule of science (Polit & Beck 2012:12). 
• Various control strategies were used such as controlling the selection of subjects 
by using a specific sampling criteria, which imposed conditions on the research 
situation, and minimised bias, as well as reducing the influence or confounding 
effects of extraneous variables (Burns & Grove 2009:35; Polit & Beck 2012:13; 
14). This was ensured by use of the inclusion and exclusion criteria. 
• Quantitative researchers gather empirical evidence; where results are grounded 
in objective reality rather than the researchers’ personal beliefs, opinions or 
assumptions (Polit & Beck 2012:14). 
• The information gathered in the study was partly quantitative and numeric 
information obtained from the records using a checklist was analysed statistically 
(Polit & Beck 2012:14). 
 
Disadvantages of a quantitative approach include: 
 
• The context of the study may be ignored, as it would not allow studying the 
phenomena in the natural setting, and therefore tight controls could not be 
ensured (Polit & Beck 2012:13, 14). 
• Requires large representative sample of the populations studied, which may not 
always be feasible, as in this study only records of the participants  were included 
which was a small sample and not representative (Polit & Beck 2012:13). 
 
A quantitative approach was necessary for this study because the researcher aimed to 
conduct a retrospective analysis of existing records to establish the disease profile of 
the participants which may have an indication of risk factors for patients from 2012- 
2015. 
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Explorative  
 
Explorative research investigates “the full nature of a phenomenon, the manner in which 
it is a manifested and other factor with which it is related” (Polit & Beck 2012:540). 
Explorative research begins with some phenomenon of interest and explores the full 
nature of that phenomenon (Polit & Beck 2012:548). The design was used to obtain 
basic information about the experiences of the DR-TB patients on their perception of 
risk factors that influence the epidemiology of DR-TB.  LoBiondo-Wood and Haber 
(2010:198) state that research is exploratory when the researcher “searches for 
accurate information about the characteristics of particular subjects, groups, institutions 
or about the frequency of a phenomenon’s occurrence, particularly when little is known 
about the phenomenon”. An exploratory design was selected as the researcher 
intended to assess and understand the experiences of these patients in a new light, ask 
questions during the in-depth interviews, and search for new insights (Polit & Beck 
2012:239). 
 
Researchers in exploratory studies must be creative, open minded, flexible and explore 
all sources of information to gather new data (Neuman 2006:34). However, exploratory 
designs are not intended for generalisation to large populations, they are designed to 
increase knowledge of the field of study (Burns & Grove 2007:359). Neuman (2006:34) 
adds that exploratory studies may be incorporated into a more systemic research that is 
published later. 
 
Descriptive  
 
The purpose of descriptive research is to “describe phenomena in real-life situations. 
Through descriptive research, concepts are described and relationships identified” 
(Burns & Grove 2007:52). Descriptive designs are commonly used in nursing research 
and are crafted to gain more information about characteristics. Their purpose is to 
provide a picture of situations as they naturally occur (Brink et al 2006:102, Burns & 
Grove 2007:237; Polit & Beck 2012:254).  
 
The research design approach utilised in this study was chosen to be relevant to the 
research questions, the theoretical statement and the research objectives. 
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The mixed methods used to answer the research question and objectives are 
described.    
 
3.6.2 Research method 
 
The research methods, as described by Pilot and Beck (2012:12), are techniques or 
procedures that researchers use for the structure and implementation of a study such 
as gathering and analysis of data relevant to the research question, problem statement 
and the study objectives. In this study the research methods included discussions on 
the population and sample selection, sample and sample techniques, sample size, data 
collection and data analysis, as well as measures to ensure validity and reliability, 
trustworthiness and ethical considerations  
 
Population and sample selection 
 
Population refers to the entire group of persons or objects that is of interest to the 
researcher, in other words, that meets the criteria which the researcher is interested in 
studying (Brink et al 2006:123). In this study, universal population referred to all DR-TB 
patients enrolled on treatment in Swaziland.  
 
According to Polit and Beck (2012:78), the target population is the aggregate of cases 
about which the researcher would like to generalise the results or findings. In this study, 
the target population is formed by patients infected with DR-TB who are treated at the 
hospital in Manzini. A sample of informants was obtained from the accessible 
population. 
 
According to Brink et al (2006:123), an accessible population is the population that the 
researcher has access to. Polit and Beck (2012:79) state that the accessible population 
is the aggregate of cases that conform to the designated criteria and that are accessible 
as subjects for a study. In this study the accessible population was the DR-TB patients 
who visited the health facility on the day of data collection and were eligible for inclusion 
to participate in the study. 
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Inclusion and exclusion criteria 
 
When researchers prepare to recruit study subjects they begin by formulating a set of 
inclusion and exclusion criteria. This is used to define who is eligible and who is not to 
be a participant. For this study, the inclusion and exclusion criteria were developed to 
ensure that participants are within legal consenting age. Within the accessible 
population the researcher considered the following inclusion and exclusion 
characteristics: 
 
Inclusion criteria 
 
For patients who will participate in the interviews should be: 
 
• DR-TB confirmed  
• Initiated and enrolled on the  DR-TB treatment during time period of study 
• Either males and females 
• 18 years old and above 
 
Exclusion criteria 
 
• Drug resistant patients initiated before or after the study period 
 
Inclusion criteria 
 
For written document analysis worksheets to be selected: 
 
• DR-TB confirmed  
• Initiated on DR-TB treatment retrospectively 
• Either males and females 
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Exclusion criteria 
 
• Documents of patients currently enrolled on treatment 
 
Sample 
 
A sample is a subset of the population which is selected to participate in a study (Polit & 
Beck 2010:307). In this study, the non-probability approach was used to recruit 
participants for the individual interviews and probability sampling method was used to 
identify the records to be included in the study. Using non-probability sampling, the 
researcher had no way of knowing whether each element of the population would be 
included or then represented in the sample and some members may have little to no 
chance of being included in the sample (Leedy & Ormrod 2005:206), however, the 
recruiting  
 
Sampling methods 
 
The recruitment method of choice was convenience sampling which fell under non 
probability sampling which by definition is when not all elements of the population has 
an opportunity for selection in the sample (Burns & Grove 2009:170). Convenience 
sampling was a method of choice to recruit participants for this study. According to 
Burns and Grove (2009:535), convenience sampling includes subjects in the study who 
happen to be at the right place at the right time, with addition of available subjects until 
the desired sample size is reached. There were a number of disadvantages 
experienced when using this sample approach: 
 
• The approach decreased the sample representativeness of the population. 
• Provided little control for biases. 
• However, serious biases were not present in convenience sampling in this study. 
 
The major advantage of the approach was that it was inexpensive, accessible and less 
time consuming.  
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However a sample that would be representative of the population was not sought for 
since generalisation was considered irrelevant in the qualitative setting because of the 
small sample size (Burns & Grove 2007:535). 
 
Random sampling 
 
Random sampling is a probability sampling technique that gives each element in a 
population the equal opportunity to be included in the study (Grove, Burns & Gray 
2013:705).  The files to study were arranged according to the patient’s surnames and a 
Kth of 7was used to select records to be analysed for this study — the records were 
arranged alphabetically in a group of 50 files. There were approximately 400 patient’s 
files and of these every seventh of the files beneath was taken for inclusion in the study 
until total of 56 files were included.  
 
Sample size 
 
The sample size in the qualitative study was not pre-determined as data was collected 
until saturation occurred. The sample size of fifty (56) written document analysis 
worksheets was randomly selected (explained in section 1.12.3). 
3.6.3 Data collection 
 
Data collection, according to Burns and Grove (2007:378), begins with identifying the 
participants and the precise, systemic gathering of information relevant to the research 
purpose, study objective, study questions or study hypothesis (Burns & Grove 
2007:536). Data collection process for the qualitative aspect of the study was through 
the individual technique. Individuals were encouraged to express and clarify in a way 
that is less likely to occur in a focus group interview (Burns & Grove 2007:379). 
 
Data collection process  
 
In this study, the individual qualitative interviews were audio recorded and transcribed 
verbatim by the researcher. 
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Individual interviews 
 
The venues were easily accessible and supported the establishment of a non-
threatening climate. The supervisors’ offices were utilised and were prepared before the 
participants arrived. These provided privacy, comfort and were free from distractions 
such as noise or other interruptions. Telephone calls were diverted for the duration of 
the interview. The interviews were conducted on different days and times. The process 
followed was as follows: 
 
• An office in a quiet place was provided for the purpose with a table and a chair 
around it for the convenience of the conversation and possible eye contact with 
one another. 
• A ‘do not disturb’ notice was placed on the door to avoid distractions or 
interruptions. 
• The sessions were held during lunch times as agreed upon with the unit 
managers and the participants. Refreshments were served thereafter. 
• Participants were requested to switch off their cell phones to avoid interruptions 
• The audio recorder was placed at the centre of the table after the methods of 
how information was recorded were explained, and permission to audiotape the 
interview was obtained from the participants. 
• The letter of permission to conduct the study was read to the participants and 
each participant was requested to sign an informed consent form. 
• The participants completed the demographic questionnaire. 
• To commence the interview, the researcher asked an open ended question, 
designed to introduce the topic and to encourage the participants to be free and 
open.  
 
The following questions were asked:   
 
What do you understand by risk factors related to DR-TB? 
 
Probing questions were directed based on the discussion generated from the opening 
questions. Some of these were as follows: 
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What do you understand by risks that influence your sickness of TB and drugs that 
seem not to help you get well?  
 
What difficulties or barriers do you experience as you care for yourself? 
 
How do you handle the identified risks? 
 
What information do you need about your condition related to risks of DR-TB? 
 
• The posing of questions and interview skills yielded better responses than 
experienced in the pre-test interview. 
• The researcher listened attentively, showed interest in individuals and put in an 
effort to understand the meaning of their basic psychological and social 
experiences as they provided information about risk factors from their point of 
view. The interview was however terminated when all the major areas were 
covered. Participants were given an opportunity to ask questions. The researcher 
thanked them for sharing the valuable information and for their time. The 
interviews were terminated when the 18th participant could not provide more new 
information, themes or categories.  
 
Data collection for the quantitative study 
 
Document interview was conducted through use of a checklist as a data collection tool.  
 
Pre-testing of the data collection instrument (checklist) 
 
According to Polit and Beck (2012:738), a pre-test is the trial administration of a newly 
developed data collection instrument. 
 
The purpose of a pre-test included the following: 
 
• Identifying problems on the research instrument such as parts of the items that 
may be difficult to be completed. 
• Evaluating and refining the data collection instrument. 
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• Assessing whether the sequencing of questions was sensible and answering the 
research question (Polit & Beck 2012:296). 
 
The data collection instrument was pretested with 5 documents that had inclusion 
criteria but were not part of the main study and the modifications were done accordingly, 
especially in terms of the sequencing of questions. 
 
The participants documents provided information such as the distribution of the 
participants by age and sex, by region, the type of drug resistance, previous treatment 
history, site of disease, HIV status, exposure to ARV’s, other comorbid conditions, 
treatment support to patients and any development of side effects or adverse reactions 
during treatment. 
 
3.6.4 Data analysis 
 
Data analysis occurred simultaneously with data collection. The eight steps provided by 
Tesch (1990) in Creswell (2013:184-187) to analyse data were mainly utilised to do the 
analysis of the qualitative data and developed themes and categories. 
 
The quantitative data from the DR-TB register were analysed through document 
analysis using content analysis approach with consultation with the statistician. 
Descriptive and inferential statistics were used to describe and summarise data, and the 
results were presented in the form of percentages, histograms, pie charts, frequencies, 
and tables 
 
3.6.5 Validity and reliability 
 
Validity 
 
The validity of the checklist tool was ensured through face and content validity through 
consultation with experts in the field who are working with the researcher at the study 
context. They made some input and some of the items on the checklist were modified. 
 
Validity is a term used to describe a measure that accurately reflects the concept it is 
intended to measure. It is the extent to which an empirical measure adequately reflects 
  
58 
the real meaning of the concept under consideration. It is a quality criterion, referring to 
the degree to which inferences made in a study are accurate and well-founded; in 
measurement, it refers to the degree to which an instrument measures what it is 
intended to or is supposed to measure (Babbie & Mouton 2001:648, 123; Polit & Beck 
2012:745). Validity varies from one sample to another and from one situation to another; 
therefore validity testing actually validates the use of an instrument for a specific group 
or purpose, rather than the instrument itself (Grove, Burns & Gray 2013:393). 
 
Face validity 
 
Face validity refers to whether or not the instrument appears to reasonably measure the 
target construct. In this study, it was an important aspect of the usefulness of the 
instrument, because the willingness of subjects to complete the instruments related to 
their perception that the instrument measured what they agreed to provide (Grove et al 
2013:394; Polit & Beck 2012:336).It was based on intuitive judgement of experts in the 
field who were the experienced medical personnel with regards to the study 
phenomena. They therefore verified that the checklist measured what was desired. 
Their input assisted the researcher to add some essential items on the checklist or 
modify some items about the study phenomena. 
 
Content validity  
 
Content validity examines the extent to which the method of measurement includes all 
the major elements relevant to the construct being measured. This evidence was 
obtained from the literature, from representatives of the relevant populations, and from 
content experts. Among the dimensions often used are the following: clarity of wording, 
relevance of the item to the construct, or to one of its dimensions, and appropriateness 
for the target population (Grove et al 2013:394-395). 
 
To ensure content validity, the researcher conducted an extensive literature review 
comprising previous studies published in research journals, as well as WHO 
publications on the study phenomena. 
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Reliability 
 
Reliability of the check list was ensured by use of the interrater reliability as the tool was 
tested by the researcher and the clerks who work with the patient’s register. 
 
3.6.6 Measures to ensure trustworthiness 
 
Measures to ensure trustworthiness in qualitative research refer to the accuracy of the 
findings by employing certain procedures (Creswell 2013:250). The following measures 
were taken into account which was credibility, dependability, transferability and 
confirmability (Brink et al 2010:118, 119). 
 
Credibility refers to confidence in the truth and interpretation of the data. The truth of the 
findings was established as the participants were accurately identified and described 
and the data obtained from participants who had personal experience of DR-TB (Polit & 
Beck 2012:539). The researcher’s credibility has to do with the faith that can be put in 
the researcher (Polit & Beck 2008:538). The researcher has several years’ experience 
working with researchers on DR-TB at the referral hospital. The researcher ensured the 
credibility of the study through prolonged engagement and use of mixed study methods. 
Prolonged engagement was through much time spent with the participants during the 
interviews and day to day contact during consultations (Polit & Beck 2008:545). 
 
Dependability  
 
Dependability refers to the stability of data over time and conditions (Polit & Beck 
2012:539). In this study, the audio-taped and transcribed information served as 
evidence that is consistent and stable. 
 
Transferability  
 
Transferability refers to the extent to which findings can be transferred or applied to 
other similar settings or groups (Polit & Beck 2012:539). The findings of this study 
cannot be generalised as it was conducted with a small size of participants who were  
identified and recruited from one hospital, although the descriptions and results or 
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findings should assist researchers to consider transfer as a possibility (Polit & Beck 
2012:541). 
 
Confirmability  
 
Confirmability refers to objectivity that is the potential congruence between two or more 
independent people about the accuracy, relevance and meaning of the data. In this 
study data collection and analysis represent the information provided by participants 
and not manipulated data by the researcher. The audio-taped information serves as 
evidence to reflect the participants’ responses (Polit & Beck 2008:541).  
 
3.7 ETHICAL CONSIDERATIONS  
 
In this study considerations were taken to ensure protection of the rights of the research 
institution, of participants, and ensuring scientific integrity.  
 
3.7.1 Protecting the rights of the research institution  
 
This research fell under the authority of the Department of Health Studies of UNISA, 
since it is conducted in order to obtain a Master’s degree in Public Health from this 
institution. Therefore, the researcher sought for official ethical approval from the 
Department’s Research Ethics Committee. Ethical clearance was obtained (Annexure 
A). Permission by the Swaziland’s Health Research Committee was also sought for. 
Moreover this research took place under the authority of the management of National 
DR-TB Referral Hospital. Therefore, after obtaining ethical approval by the Ethics 
Committee of the Department of Health Studies a letter of application for permission 
(Annexure B) to conduct this research was sent to the National Tuberculosis Control 
Program and the management of the respective facility. 
 
3.7.2 Protecting the rights of the participants 
 
Polit and Beck (2012:152) describe principles and procedures that researchers ought to 
adopt to protect the rights of participants. The Belmont report articulated three broad 
principles upon which standards of ethical conduct in research are based; which include 
beneficence, respect for human dignity and justice (Joubert & Ehrlich 2007:31). The 
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rights of the participants were also protected by obtaining informed consent (see 
Annexure D), protecting their right to withdraw from the study at any given time if they 
feel uncomfortable, respecting their right to confidentiality and anonymity, as well as 
maintaining privacy and dignity.  
 
Beneficence 
 
Human research should be intended to produce benefits for the participants, by 
avoiding, preventing and minimising harm and maximising benefits. In research with 
humans, harm and discomfort can be: physical such as stress, fear, fear, loss of social 
support or financial loss of wages (Polit & Beck 2012:152). Since this research concerns 
identifying risk factors related DR-TB which may be a sensitive subject, and may bring 
about emotional discomfort.  
 
A counsellor based at the hospital was arranged to be available during data collection 
for participants who may be emotionally affected by the interview. However, in this study 
none of the participants suffered emotional discomfort but rather most of them were 
amused by the questions.  
 
The researcher ensured that all involved in the study respected the views of the 
participants and ensured that participants were not exposed to any emotional stress as 
a result of the study itself. The study involved minimal risk, which is defined as risks no 
greater than those ordinarily encountered in daily life, or during routine tests and 
procedures (Polit & Beck 2012:733).  Participants were informed about the benefits for 
the advancement of knowledge that may improve the reproductive quality of life for 
women.  
 
Respect for human dignity 
 
The cardinal principle of respect for human dignity includes the right to self-
determination and the right to full disclosure. Self-determination means that prospective 
participants are able to voluntarily decide whether or not they want to take part in the 
study without the risk of prejudicial treatment. Participants have the right to ask 
questions, to refuse to give information, and to withdraw from the study. With regards to 
full disclosure in this study, the researcher fully described the nature of the study, the 
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persons’ right to refuse participation without victimisation, as well as likely risks and 
benefits (Polit & Beck 2012:154). 
 
To ensure respect for human dignity in this study, participants were briefed about the 
benefits and risks and their right to refuse and /or withdraw from the study, before they 
signed the consent form, and without any form of coercion. They were further able to 
ask questions without encountering judgement or intimidation of any kind. 
 
Justice 
 
The cardinal principle of justice includes the participants’ right to fair treatment and the 
right to privacy. Participants’ selection should be based on study requirements, and not 
on a group’s vulnerability. The right to fair treatment means that researchers must treat 
people who decline to participate or who withdraw from the study after initial agreement 
in a non-prejudicial manner; that they must honour all agreements made with 
participants and demonstrate respect for the beliefs, habits and lifestyles of people (Polit 
& Beck 2012:155). 
 
In this study, all participants were selected by convenience sampling, as long as they 
fulfilled the inclusion criteria in a fair manner, and without coercion. 
 
Informed consent 
 
Informed consent meant that participants have access to adequate information about 
the research, that they comprehend that information and that they have the ability to 
consent to or decline participation voluntarily (Polit & Beck 2012:159). In this research, 
in order to satisfy this ethical requirement, a written informed consent explaining the 
objectives and potential risks, as well assuring confidentiality of the study, was 
presented to each respondent. It was also explained that the respondent could withdraw 
from the study at any time. The participants signed the consent form in order to show 
that they voluntarily accept the right to participate in the study (Polit & Beck 2012:156). 
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Right to withdraw from the study 
 
Participants were informed about the option to withdraw or discontinue participation in 
the study at any time, without any penalty or loss of benefit or intimidation as a regular 
patient in the health facility 
 
Confidentiality and anonymity 
 
Confidentiality involves the researchers’ management of private information shared by a 
subject, which must not be shared with others without the subject’s expressed consent 
(Burns & Grove 2005:196). 
 
Anonymity exists if the subject’s identity cannot be linked, even by the researcher, with 
individual responses (Burns & Grove 2005:196). Polit and Beck (2012:720) further 
clarified that it involves the protection of respondent’s confidentiality, such that even the 
researcher cannot link individuals with the information provided). 
 
In this study, to ensure confidentiality and anonymity, the participants were assured that 
all their responses and information obtained from them during the study would neither 
be disclosed nor publicly divulged.  
 
Maintaining privacy 
 
Privacy is an individual’s right to determine the time, extent, and the general 
circumstances under which personal information will be shared with or withheld from 
others. This information consists of one’s attitudes, behaviours, opinions and records 
(Burns & Grove 2005:195). 
 
The researcher ensured that the research was no more intrusive than it needed to be, 
and that the participants’ privacy was maintained and the data kept with strict 
confidence. Questionnaires were completed in a private venue designated for that 
purpose. A “do not disturb” sign was hung at the door to reduce the impact of external 
noise and distractions. 
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3.7.3 Scientific integrity of the research 
 
The researcher will adhere to the principles of scientific integrity by avoiding plagiarism. 
These will include: honesty in reporting, referencing and communicating the findings. 
 
Privacy and confidentiality will be maintained by keeping all data obtained under lock 
and key.  
 
Anonymity may be difficult to maintain but all measures to protect the participants will be 
ensured. They will be informed that they may withdraw from the study at any time 
without victimisation.  
 
Scientific integrity will be ensured through avoiding plagiarism, acknowledging all 
sources used and writing the correct list of sources. 
 
3.7.4 Dissemination of findings 
 
The findings will be published in an accredited journal for wider readability; a poster will 
be developed and presented through in-service education to patients and staff. 
 
3.7.5 Scope and limitations of the study 
 
The scope of this study was limited because of the small sample size of the qualitative 
part and it was not easy to generalise or transfer results or findings to a wider 
community. Although some information was obtained from the register it could have 
variables that were inaccurate or incomplete.  Some of the participants had a challenge 
with the English language and the researcher mostly translated the questions into Swazi 
language.  
 
3.8 CONCLUSION 
 
This chapter described the research design and methodology used in conducting this 
study as a mixed method approach. The researcher used a quantitative, explorative and 
descriptive study design, and a check list was used to collect data from documents. 
Qualitative data was collected through use of an interview guide and 18 individuals were 
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interviewed. The chapter included discussions on the research setting, population, 
sample and sampling technique, data collection approach and method, data analysis, 
measures to ensure validity and reliability, trustworthiness and ethical considerations.  
 
Chapter 4 discusses the data analysis and interpretation of the research findings. 
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CHAPTER 4 
 
ANALYSIS, PRESENTATION AND DESCRIPTION OF THE RESEARCH 
RESULTS 
 
 
4.1 INTRODUCTION 
 
Data analysis is the systematic examination of data to discover conceptual patterns and 
in some cases, cause-and-effect associations within the broader social context in which 
the research question and objectives are directed (Ulin, Robinson & Trolley 2005:139).  
 
The purpose of this study was to identify risk factors influencing epidemiology of drug 
resistant tuberculosis (DR-TB) in a drug resistant hospital setting. This was done by 
considering analysed information obtained from the questionnaire items. This was to 
determine whether the participants that had eventually developed DR-TB had similar 
occurrences or events leading to them finally being diagnosed with this type of TB 
resistance. The quantitative (Section A) employed document analysis using content 
analysis approach, and was done with consultation with the statistician. The qualitative 
(Section B) data analysis was done through thematic analysis. Quantitative data was 
obtained from patient files and registers and qualitative data through individual 
interviews.  
 
Research question  
 
“What are the risk factors that influence DR-TB occurrence among patients enrolled on 
DR-TB treatment?” 
 
The objectives of this study were to: 
 
• explore and describe the risk factors influencing the epidemiology of DR-TB 
amongst patients enrolled on DR-TB 
• identify risk factors influencing the epidemiology of DR-TB amongst patients 
enrolled on DR-TB treatment 
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• develop a poster that will exhibit the research process undertaken and the 
findings 
 
SECTION A: Quantitative analysis of data 
 
4.2 RESEARCH RESULTS BASED ON DEMOGRAPHICS 
 
Most of the demographics in figures are of the live patients.  Some aspects of analysis 
are alluding to information from the retrospective patient files that were randomly 
selected for analysis of 49 patients that had been treated and completed Drug resistant 
treatment. Initially 56 files were identified but 7 were incomplete and spoiled and were 
therefore not included. 
 
Data management and analysis 
 
Eighteen (18) participants participated in the study on face to face interviews and 
collected data was analysed through thematic analysis. The checklist was administered 
to 49 respondents identified on the register.  Data were coded and analysed using the 
SPSS version 13.0 statistical software packages and excel in consultation with a 
statistician. Descriptive statistics such as frequency distributions, medians, contingency 
tables and percentages were obtained.  A 95% confidence interval of proportions was 
constructed. 
 
4.2.1 Demographics 
 
The researcher did own analysis based on vast experience of use of the SPSS 
computer program with the help and validation of a statistician.  Analysis was  basically 
related to the  demographic variables such the participant’s  age and sex, region where 
they are staying, level of education, employment, job loss due to illness, total cost  per 
facility visit, previous treatment history and perception by patients for risk factors for 
developing DR-TB. 
 
Age and sex are important determinants of people’s likelihood to take health actions as 
guided by the HBM. 
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Figure 4.1:   Age and sex (n=49) 
 
Majority of the active patients who were interviewed were falling in the 20-29 age group, 
followed by the 30-39 age group, 40-39 and lastly 10-19.This trend suggest that the 
mostly highly likely to develop drug resistant TB are those falling between the 
reproductive age group and this can be validated using the secondary data collected 
from the 49 patients where it shows the same trend in age. The reason for the 
reproductive age group to be most affected is that this is the same group that is highly 
affected by HIV and Holland K also stated that HIV positive have a weakened immune 
system as a result are prone to opportunistic infections such as tuberculosis.  
 
The following figures (4.2, 4.3 and 4.4) of age and sex and are displayed to portray a 
picture of affected patients as deduced from the files for the years 2011, 2012, 2013. 
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Figure 4.2:   Age and sex 2011 (from files) (n=49) 
 
 
 
Figure 4.3:   Age and sex 2012 (from files) (n=49) 
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Figure 4.4:  Age and sex 2013 (from files) (n=49) 
 
The graphs above shows the distribution by age and sex of the patients from the files 
and registers, the results shows that at ages 20 and below the number of infection from 
DR-TB is low then the number gradually increases from ages 25-45 being at peak at 
ages 31-35. This shows that the most affected group is the reproductive age group 
which is also the highly infected by the HIV virus which could be the reason for this 
trend.   
 
Another trend that can be identified from the graph is that the prevalence in 2011 has 
been gradually increasing in 2012 and is even higher in 2013 amongst all the sexes e.g. 
the males in 2013 are higher than the ones in 2012 which are also higher than the male 
in 2011, this is the similar case for the females as well. This suggests that DR-TB trend 
is continuously increasing even though in the country TB is gradually going down. 
 
Understanding a population’s age and sex composition yields insights into changing 
phenomena and highlights future social and economic challenges. (United States 
Census Bureau 2015:11).  
 
The population’s age was assessed from the years 2011-2013 to understand the 
concentration of DR-TB in relation to age and sex.  
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Table 4.1: Age groups 
 
Chi-Square Tests 
 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 21.778a 28 .791 
Likelihood Ratio 25.261 28 .614 
Linear-by-Linear Association .064 1 .800 
N of Valid Cases 50   
 
a. 38 cells (95.0%) have expected count less than 5. The minimum expected 
count is .04. 
 
Table 4.1 shows that Pearson Chi-square statistic, X2 =21.778 and p>0.05.The data 
does not support the claim that age influences the chances of developing DR-TB. There 
is no enough evidence to say age is a predictor of drug resistance.  
 
4.2.2 Distribution of patients by region 
 
The DR-TB patients were coming from different regions in the country Hhohho, Manzini, 
Lubombo and Shiselweni. 
 
 
Figure 4.5:   Distribution of patients by region (from files) (n=49) 
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Figure 4.5 shows that 46% of the respondents were from the Manzini region; these 
were then followed by Hhohho and Lubombo both with 27%. None of the respondents 
were from Shiselweni region and this is probably due to that Shiselweni offers DR-TB 
treatment in 3 health facilities in their region where patients prefer to access their care 
from mainly due to easier access.  
 
4.2.2.1 Level of education 
 
The majority (56%) of the participants had not completed their high school education.   
 
 
Figure 4.6:  Level of education (n=18) 
 
Figure 4.2 shows that there is little association between low education and development 
of DR-TB as 56% of the respondents were educated and 44% had not completed their 
O’level/IGCSE education. According to Desalu, Adeoti, Fadeyi, Salami, Fawibe and 
Oyedopo (2012:1), the association of higher family income and education with 
awareness of TB signs may be attributed to higher literacy. Higher level of educational 
attainment is often a factor for better family income. Families that have high income are 
able to purchase household assets like television, radio and Hi fi internet, and other 
communication appliances that increase their knowledge of health-related matters which 
are of public concern (Desalu, Adeoti, Fadeyi, Salami, Fawibe and Oyedopo (2012:1). 
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4.2.2.2 Employment history 
 
Employments as a means to financial viability play a vital role to positively deal with risk 
factors related to DR-TB disease. Figure 4.3 exhibits the employment history of the 
participants.   
  
 
Figure 4.7:   Employment history (n=18) 
 
Twelve (67%) of the participants were employed at diagnosis with TB, 6 (33%) were not 
employed, of the 12 only 4 (33%) were able to keep their jobs which means 8/12 (67%) 
lost their jobs due to tuberculosis. Some of the participants stated that they would leave 
the jobs with an agreement that once they get better they will be re-instated in their 
previous positions and only 1 was. Some would just stop going to work due to ill health. 
According to Phelamei (2013:13), HIV and TB are also intricately linked to social 
situations such as malnutrition, unemployment, alcoholism, drug abuse, poverty and 
homelessness that reduce people to being vulnerable groups to diseases. 
 
4.2.2.3 Job loss due to illness 
 
Illness’ compromises one’s ability to seek for a job or be sustained in a job due to 
demands for doctors’ appointments or consultations. 
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Figure 4.8:  Job loss (n=18) 
 
Twelve of the participants were employed at diagnosis with TB, 6 were not employed, of 
the 12 only 4 were able to keep their jobs which means 8/12 (67%) lost their jobs due to 
tuberculosis. Some of the participants stated that they would leave the jobs with an 
agreement that once they get better they will be re-instated in their previous positions 
and only 1 was. Some would just stop going to work due to ill health. 
 
4.2.2.4 Total cost per facility visit 
 
Visit to the health care facilities have escalating cost that lead to some patients 
defaulting treatment. 
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Figure 4.9:   Total cost per facility visit (n=18) 
 
Cost of seeking DR-TB care for the participants was another factor that was closely 
related to access. The researcher noted that participants that were accessing their 
tuberculosis medication previously before being started on DR-TB treatment that on 
average a patient would spend R90 for a facility visit and 78% of the participants were 
without a job (8 had lost their source of income, and 6 were without jobs at diagnosis). 
 
According to WHO (2015:3: Figure 4.10) falling ill with TB often carries a devastating 
financial burden with social repercussions. On average, TB patients in low-and middle-
income countries face medical expenses, costs of seeking/staying in care, and income 
loss equivalent to more than 50% of his or her annual income. The financial burden 
varies between settings, with total cost in relation to income ranging from 2% to over 
300% across countries with different TB care models, general health systems and social 
protection schemes. The financial burden is on average greater for persons ill with 
MDR-TB and for the poorest (WHO 2015:3) 
 
Income loss represents on average about 60% of the total costs faced by patients, 
whereas about 25% is for direct medical costs such as tests, medicines and 
hospitalisation, and the rest is for other care-related costs, such as transport (see 
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figure). On average, half of the costs are incurred before TB treatment has begun – in 
seeking diagnosis (see figure).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10:  Cost of TB 
(Adapted from WHO 2015:3) 
 
Patients often have to resort to survival means to cope with their situation: up to 75% of 
TB patients must take out a loan; up to 50% sell household items; and up to 66% rely 
on financial support from relatives. In Swaziland the patients identified more with relying 
on relatives for support which meant that whether the patient adheres to treatment 
appointments heavily depends on the relatives. 
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4.2.2.5 Previous treatment history 
 
 
Figure 4.11:  Previous treatment history (n=49) 
 
The trend in both secondary and primary cohorts shows that the majority of patients 
have been exposed to first line drugs (FLD’s) prior to developing DR-TB, with the 
current findings from patients who are still taking the drug resistant medication showing 
that 50% have been exposed to FLD’s, and 44% had no prior exposure.  
 
The secondary data finding (the cohort of patients (n=49) who were treated and have 
treatment outcomes shows that 73% were exposed to FLD’s prior to developing drug 
resistant TB, 23% had no prior exposure to TB drugs. The researcher interpretation to 
this change in the trend is that in previous years 2011, 2012 and 2013 majority of those 
infected with drug resistant tuberculosis it was mainly from prior exposure to the TB 
drugs. The current findings suggest an increase in direct transmission of drug resistant 
TB in our communities as more and more drug resistant cases report that they have 
never been treated for TB before. 
 
This would then bring the question why is there increase in direct contact infection over 
the years? The researcher would conclude that previously the number of DR-TB 
patients was mainly from poor treatment adherence or poor compliance which meant it 
was a result of poor treatment outcomes but this number of DR-TB patients resides in 
0%
10%
20%
30%
40%
50%
60%
70%
80%
Previously
Treated by FLD
Previously
Treated by SLD
No previous
history
No  record
% 73% 0% 23% 4%
Ax
is 
Ti
tle
 
Previous Treatment History 
  
78 
the communities and workplaces and is directly transmitting the already resistant TB to 
people who have never been exposed to TB medication. 
 
The chi-square test rejected the null hypothesis that previous treatment history is 
associated with progression to DR-TB. The data suggests that there is not enough 
evidence to support the claim, therefore there is no significant association between 
previous treatment history and DR-TB. 
 
Side effects during TB treatment and DR-TB 
 
In this example, since the p-value is .040 (which is less than .05), we can say that there 
is a significant association between development of side effects during TB treatment 
and progression to DR-TB. According to Luetkemeyer (2013:1), the risk of developing 
adverse reactions to TB treatment is higher in HIV-infected individuals than in HIV-
uninfected individuals, occurring in approximately 25% and 13%, respectively. 
Hepatotoxicity is common in the treatment of TB in HIV-infected patients. The adverse 
reactions may be made worse by use of both tuberculosis and antiretroviral (ARV) 
drugs. Other drug to drug interactions which may be fatal with TB treatment include 
antibiotic medications such as fluconazole and trimethoprim-sulfamethoxazole, by 
coinfection with viral hepatitis, or by pre-existing liver disease. 
 
4.2.2.6 Perception by patients for risk factors for developing DR-TB 
 
 
Figure 4.12:  Perception by patients on reasons for developing  
drug resistant tuberculosis (n=18) 
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The majority (39%) of the patients did not know how they got to develop drug resistant 
TB and a majority of those infected didn’t know as they were never treated for TB 
before. The next group 22% stated infection from family members, 11% said it was 
working with cement, 11% said it was due to smoking and alcohol, 11% said it was 
because they had TB that caused them to develop DR TB and 6% related drug resistant 
TB to HIV.  
 
SECTION B: Qualitative data analysis 
 
4.3 PARTICIPANT DEMOGRAPHICS 
 
The participants comprised of eighteen Swazi patients who were all currently 
undergoing DR-TB treatment. There were more single young adults than those that are 
married among the participants. Drug resistant TB seemingly affects more females than 
males as the trend showed that 11/18 females and 7/18 were males. This could be due 
to the higher population ratio of female to male ratio in the general population. 
 
Eighteen individuals were interviewed until saturation of data occurred. Demographic 
information was collected at the beginning of each interview using a questionnaire with 
predetermined fields based on the variables that would contribute to the analysis of the 
study phenomenon. The use of the concept ‘participant’ as referring to the patients who 
were the target population for this study was used interchangeably.  
 
An interview guide was administered to collect data which had section A for the 
demographic questionnaire, Section B for the grand tour question. Participants were 
required to respond to the main question and probing questions about their experiences 
prior to being diagnosed with drug resistant TB. They were also encouraged to reflect 
on any occurrences that may have led to their eventual DR-TB diagnosis during TB 
treatment or otherwise.  
 
The individual interview method as suggested by Polit and Beck (2012:341) was 
followed wherein a grand tour question open-ended question was asked and was 
supported with probing questions to ensure all thematic areas are covered.  
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The interview remained flexible and allowed the participants to engage in storytelling as 
they were encouraged to openly and freely respond to all the questions listed below.   
 
Participants that were interviewed were 18 in total and the following thematic areas 
were used to present the analysis: History of TB in the family and previous treatment 
history, attitude of the health care workers, healthcare worker patient education, 
accessibility to medication and pill dosing , knowledge of general factors resulting to TB, 
geographic location to facility, employer attitude to TB patients, treatment supporter 
responsibilities, Adherence and counselling, patient side effects, co-infection and 
opportunistic infections, IPC issues, and stigma. These were categorised as follows: 
 
4.4 THEMES AND CATEGORIES ON RISK FACTORS FOR DR-TB  
 
4.4.1 Theme 1: History of TB in the family and previous treatment 
 
The trend in both secondary and primary cohorts shows that the majority of patients 
have been exposed to first line drugs (FLD’s) prior to developing DR-TB with the current 
findings from patients who are still taking the drug resistant medication showing that 
50% have been exposed to FLD’s, and 44% had no prior exposure.  
 
The secondary data finding (the cohort of patients  (n=-49) who were treated and have 
treatment outcomes shows that 73% were exposed to FLD’s prior to developing drug 
resistant TB, 23% had no prior exposure to TB drugs. The researcher interpretation to 
this change in the trend is that in previous years 2011, 2012 and 2013 majority of those 
infected with drug resistant tuberculosis it was mainly from prior exposure to the TB 
drugs but of late the trend shows that there is increase in direct transmission of drug 
resistant TB in our communities and more and more drug resistant cases report that 
they have never been treated for TB before. 
 
This would then bring the question why is there increase in direct contact infection over 
the years? The researcher would conclude that previously the number of DR-TB 
patients was mainly from poor treatment adherence or poor compliance which meant it 
was a result of poor treatment outcomes. These DR-TB patients reside in the 
communities and workplaces and are directly transmitting the already resistant TB to 
people who have never been exposed to TB medication. One of the participants said: 
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“I was staying with someone who had drug resistant TB without being aware 
that she had resistant TB.” 
 
Another patient when asked what she thinks caused her to have DR-TB she responded: 
 
 “I started TB medication then stopped the medication. I was very angry and 
eventually stopped working too.” 
 
Infection prevention and control in addition to treatment completion should form a vital 
part in tuberculosis control so as to minimise direct transmission to others. 
 
4.4.2 Theme 2: Attitude of the health care worker 
 
The majority of the patients said the relationship with the health care workers was good 
13/18, those who said it was okay were 2/18 and 3 said it was bad. One of those saying 
it was bad was 44 year old single Dudu who when asked about side effects mentioned 
weakness, hallucinations and dreams, skin problems and when asked how she 
managed them she stated: 
 
“… it got better with time without reporting  because nurse never did anything, I 
think they didn’t like me.” 
 
“… there was bad language especially from gossips by the cleaners as they 
became friends with other patients.” 
 
If a patient feels that the relationship is not good with the health care worker she may 
keep whatever problems she has and solve them her own most likely wrong way. 
 
Other responses were positive: 
 
“ it was good they still recognise me.” 
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4.4.2.1 Category 2.1: Health care worker patient education 
 
The participants showed that there was a gap in tuberculosis education, this was 
evident when the participants were asked what they perceived to be the cause of them 
developing DR-TB and if they thought TB was curable. The participants stated various 
reasons some of which were not relevant to TB such as use of cement. 
 
4.4.2.1.1 Subcategory 2.1.1:  Knowledge of general risk factors resulting to TB 
 
The majority 7/18 (38.8%) of the participants interviewed stated poor adherence to 
treatment/ not completing treatment and direct infection by contact as the major factors 
resulting to development of drug resistant tuberculosis. These were followed by 
smoking, dust, and poor diet. Other factors mentioned included HIV, by poor education 
and counselling, public transport, sex, working in mines, stress, unemployment, 
mismanagement and being emotional. 
 
Another risk factor is that patients that are HIV/TB co-infected, these diseases do not 
normally get the same attention where even the structure of care shows the 
discrepancy. During adherence counselling HIV is provided with 3 sessions before the 
patient is started on the treatment, yet TB is only given a few minutes session and the 
patient is initiated on treatment. 
 
4.4.2.2 Category 2.2: Accessibility to medication 
 
The cost for the participants was another factor that was closely related to access. The 
researcher noted that participants that were accessing their tuberculosis medication 
previously before being started on DR-TB treatment that on average a patient would 
spend R90 for a facility visit and 78% of the participants were without a job (8 had lost 
their source of income, and 6 were without jobs at diagnosis). One of the participants 
said: 
 
“To go for review at the facility a car was hired to take me because I was too ill, it 
cost R400 each trip and I was not employed my sister paid it for me.” 
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Geographic access proved to be another risk factor as 11/18 majority of the patients 
were from the rural health settings. In the country health care facilities are closer at the 
urban areas meeting the recommended 8 km radius by WHO. In rural areas the facilities 
are fewer and further apart making it cumbersome for patients to reach the facilities.  
Another factor is that TB services are not provided in all these facilities. This not only 
makes the facilities to be inaccessible to the patients but if accessible the TB service 
itself not being accessible as it is not provided in that facilities.   
 
4.4.2.3 Category 2.3:  Adherence counselling and education 
 
In tuberculosis and HIV care adherence counselling is done by the health care workers. 
Looking at the structure of adherence counselling in other chronic diseases like HIV 
where there are 3 sessions of counselling done for the patient before initiating 
treatment, TB does not have such an intense structure to ensure importance of 
adherence to treatment. When asked on adherence counselling being done at the 
beginning of treatment 12 agreed they were counselled, though some in the 12 said 
they were too sick to understand what was being said. Six said they were not well 
counselled and a majority was those that were diagnosed with DR-TB without previous 
history of TB. One participant said: 
 
“I was diagnosed at X facility in Manzini where they told me I had DR-TB and had 
to go to Moneni hospital, when I got here I was told I am being admitted to the 
ward for TB, it was when in the ward that i heard from the other patients that I will 
stay here for a long time since I was highly infectious until I complete my 
injections- I ended up staying in hospital for 8 months.” 
 
Nineteen year old Mandisa asked after the interview: 
 
“How long will I be taking the medication.” 
 
The response given was that it will be 8 months of injections and at least 2 years 
medication. She was also informed that side effects may crop up but she should report 
these to the facility as soon as possible she broke down and cried.  This is the same 
day she was to start the 2 year long DR-TB medication and she was emotionally not 
ready, and the information was new to her. 
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The majority (39%) of the patients did not know how they got to develop drug resistant 
TB and a majority of those that didn’t know were never treated for TB before. The next 
group 22% stated infection from family members, 11% said it was working with cement, 
11% said it was due to smoking and alcohol, 11% said it was because they had TB that 
caused them to develop DR TB and 6% related drug resistant TB to HIV.  
 
4.4.2.4 Category 2.3:  Treatment supporter responsibilities 
 
Table 4.1: Treatment supporter 
 
Yes 7 70% 
No 3 30% 
Never treated for TB (N/A) 8  
 
The participants who were interviewed were 18 in total, of these 10 were treated for 
tuberculosis before, of the 10, 7 had treatment supporters linked to their care, 3 did not 
have a treatment supporter and 8 were never treated for TB before. The researcher 
identified that the greater majority 70% of those previously treated were linked to a 
treatment supporter and mostly it was family treatment supporters. There are 3 types of 
treatment support structures in the country the family treatment supporter, the 
community treatment supporter and the facility treatment supporter. The treatment 
supporter responsibilities are to assist the patient in the taking of the medication, 
including reminding the patient when it is time to take medications, to remind patient of 
hospital visits, to monitor the patient when taking the medication and remind on the 
correct dosing of the drugs etc. These responsibilities require the treatment supporter to 
be close to the patient which is not usually the case so this results in some of the 
treatment supporters not being able to fulfil their responsibilities and in turn affect the 
patient intake of their medication (Swaziland National Drug-Resistant Tuberculosis 
Management Guidelines 2012). 
 
During diagnosis twelve of the participants were employed, a total of 8 lost their jobs 
with only 4 being able to maintain their jobs. One participant stated that: 
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“We had an agreement with the employer to stop work and once my health 
improves I will be re-instated, when I got better someone had already taken my 
position, I was jobless.” 
 
The support and understanding of employers is crucial to for patients with DR-TB for 
their quality of life. 
 
4.4.3 Theme 3: Stigma 
 
The participants when asked about disclosure to community for support raised issues of 
fear of stigma as a reason why they are not disclosing their TB status. Eleven (11/18) 
stated that they did not have any community support, of the eleven, 9 stated fear of 
discrimination and isolation from community. One participant stated: 
 
“I did not disclose because the community I stay in is not a good community.” 
 
Another participant who is the fourth TB case in the family where both parents and a 
sister died of TB said: 
 
“No but the community is aware that I am from a family of TB affected people.” 
 
This statement gave the impression that the community has labelled the homestead to 
be the “TB stricken family”. 
 
On a more positive note one of the patients felt like this about stigma: 
 
“No by the way what I have realised by stigmatisation is that it usually starts with you, I 
never blamed anyone for my status.” 
 
In areas of high HIV prevalence, where HIV and TB co-infection is common, the link 
between the two diseases has contributed to the stigmatisation of TB. TB is perceived 
as a marker for HIV positivity; therefore, HIV-associated stigma is transferred to TB-
infected individuals. Other causes of TB stigma include the perceived associations of 
TB with malnutrition, poverty, being foreign-born, and low social class. As with HIV, TB 
is stigmatized in this context because it is linked to other disvalued characteristics, 
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which themselves are also social determinants of health. Finally, TB stigma may occur 
because an affected individual's community believes he or she must have done 
something to deserve to be infected. This judgment may reflect the belief that TB is 
divine punishment for a moral or personal failing, which then licenses stigmatisation. 
 
TB-infected individuals perceive themselves to be at risk for a number of stigma-related 
social and economic consequences. Because the most common result of TB stigma is 
isolation from other members of the community, TB infection can substantially impact 
economic opportunities. (Courtwright et al 2010). 
 
According to Courtwright et al (2010), in areas of high HIV prevalence, where HIV and 
TB co-infection is common, the link between the two diseases has contributed to the 
stigmatization of TB. TB is perceived as a marker for HIV positivity; therefore, HIV-
associated stigma is transferred to TB-infected individuals. Other causes of TB stigma 
include the perceived associations of TB with malnutrition, poverty, being foreign-born, 
and low social class. As with HIV, TB is stigmatized in this context because it is linked to 
other disvalued characteristics, which themselves are also social determinants of 
health. Finally, TB stigma may occur because an affected individual's community 
believes he or she must have done something to deserve to be infected. This judgment 
may reflect the belief that TB is divine punishment for a moral or personal failing, which 
then licenses stigmatisation. 
 
TB-infected individuals perceive themselves to be at risk for a number of stigma-related 
social and economic consequences. Because the most common result of TB stigma is 
isolation from other members of the community, TB infection can substantially impact 
economic opportunities. 
 
4.5 CONCLUSION 
 
A mixed method approach was undertaken in this study to identify risk factors related to 
DR-TB from patients who were enrolled for treatment. Data analysis of both documents 
and active patients (these are the patients who were currently undergoing DR-TB 
treatment) provided a picture that assisted to make deductive conclusions on the study 
phenomena. 
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The results and findings of this study helped to formulate conclusions and 
recommendations made in chapter 5. 
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CHAPTER 5 
 
DISCUSSIONS, CONCLUSIONS AND RECOMMENDATIONS 
 
“Prevention is better than cure” 
 
 
5.1 INTRODUCTION  
 
In this chapter the findings and results of the study on risk factors influencing the 
epidemiology of DR-TB in TB Hospital are discussed and concluded. 
 
The study findings were discussed in relation to literature and conclusions were drawn. 
The limitations, recommendations and implications relating to nursing practice, 
education, further research and how a poster will be structured were presented. 
 
5.2 RESEARCH QUESTION 
 
The main and probing questions asked were: What are the prime risk factors of drug 
resistance TB? The control measures currently in place, are they effective in eliminating 
any form of TB in Swaziland. Does the TB treatment success rate reflect the prevailing 
status of TB in Swaziland in light of drug resistance TB? Does previous treatment with 
other anti-tuberculosis fuel the progression to DR-TB? 
 
5.2.1 Research objectives 
 
• To investigate the factors that influences the emergence of DR-TB in Swaziland. 
• To establish the relationship between DR-TB and HIV. 
• To develop a poster that will portray the findings on risk factors influencing the 
epidemiology of DR-TB. 
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5.3 DISCUSSIONS AND CONCLUSIONS ON THE MAJOR FINDINGS 
 
The findings of this study were based on the purpose and objectives of the study. They 
are discussed in this section as an integrated summary of results derived from the data 
and related to literature.  
 
To investigate the factors that influences the emergence of DR-TB in Swaziland 
 
Previous treatment history 
 
The researcher arrived at the conclusion that the major factors contributing to the 
emergence of DR-TB are previous treatment with anti-tuberculosis drugs, human 
immune virus, and lack of education for patients especially during transfer between 
facilities, where referring facility assumes education will be done in receiving facility and 
vice versa and education of the patient’s families on precautionary measures to take 
when caring for a family member, and what to do in cases of developing side effects, 
which other studies validate. 
 
In a study conducted in Portugal, Gomes, Correia, Mendonca and Duartes (2014:12) 
concluded that DM, previous treatment history and intravenous drug use were the major 
risk factors identified in the study. Pinto and Menzies (2011:18) suggest that poor 
management of susceptible tuberculosis (previously treated TB) propagates the 
emergence of DR-TB.  During treatment three possible mechanisms can result in the 
selection of drug-resistant mutant strains: treatment with an inadequate number of 
effective drugs, sub-therapeutic dosing or absorption, or treatment interruption (Pinto & 
Menzies 2011:18). Patient consumption of all doses of an appropriate drug regimen with 
the correct dosages is essential to prevent resistance. The value of evidence-based 
adequate drug regimens cannot be over-emphasized; unfortunately, these seem to be 
flouted in countries where drug regulatory systems are lax, and private physicians and 
pharmacies are allowed to prescribe drugs in an unregulated manner. They further state 
that when treated with a single drug, the population of TB bacilli initially shrinks due to 
the killing of susceptible organisms in the population, often rendering a person smear-
negative (as a result of fewer organisms being present). However, the organisms that 
survive the initial phase are the drug-resistant mutants, and the proliferation of these 
mutants eventually causes the entire population of bacilli to be replaced by drug-
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resistant forms that continue to proliferate until they are numerous enough to cause 
recurrence of symptoms, and smear positivity; this is termed “the fall and rise 
phenomenon.  
 
Unemployment and job losses due to TB: Socio-economic factors were also identified 
as strong determinants of patients seeking health related care which may also affect the 
actual access of care due to unemployment and having to travel long distances to 
facilities. This can also affect reporting of side effects on time at facilities as patients 
would rather wait until they return to the facility for review to bring up issues related to 
medication. The patient health care worker relationship also plays a major role when it 
comes to reporting side effects and four of the participants reported vomiting as a side 
effect which could result in sub optimal drugs in their system for cure. 
 
Another risk factor identified to be related was the number of patients who reported 
having lost their jobs due to diagnosis with TB, as 8 out 12 reported some form of 
interruption of financial gain as a result of TB. Only one was able to regain her job after 
being cleared by the medical officers, during this time the patients need the income to 
take care of themselves and their families rely on their income. Job loss means the 
patients will have to rely on others to travel to the facility to get treatment though the TB 
treatment is free in all public facilities and this renders the patients helpless on financing 
for their own health care. 
 
To establish the relationship between DR-TB and HIV 
 
The relationship between DR-TB and HIV was identified in both cohorts. The qualitative 
findings show that the prevalence of HIV in DR-TB was 61% for HIV positive and 39% 
for negative and the quantitative data showed 77% HIV positive and 23% negative to 
HIV. Both these data sets show that there is a close link between DRTB and HIV.  
 
A classical research study by Goble, Iseman, Madsen, Waite, Ackerson and Horsburgh 
(1993:527) although old but came out with critical findings that confirmed that many 
patients who contracted drug resistant TB have HIV infection, their response to 
treatment appears to be very poor with high rates of treatment failure and mortality. 
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5.3.1 Recommendations 
 
• Intensification of active case finding strategies among HIV positive population: 
measures that will allow early identification of DR-TB such as the universal use of 
the TB screening tool in all HIV care settings.  
• Strengthening health education in facilities even if the patient is from another 
facility to ensure that the important information is communicated to both the client 
and the family. 
• The integration of Infection, Prevention and control measures in all health care 
planning. This should start with the planning structures in facilities, ensuring 
health education of the patients and their families to avoid feelings of 
discrimination and bring understanding on need for some of the precautionary 
measures in the control of TB. 
• Regimens for drug-susceptible TB have a strong evidence base and, when 
employed in the right dosages for the right duration with close monitoring of 
adherence, lead to high cure rates without the development of drug-resistant 
strains. Getting treatment right the first time should therefore be the primary 
focus of TB control programs worldwide. 
• Infection prevention and control in addition to treatment completion should form a 
vital part in tuberculosis control so as to minimise direct transmission to others. 
 
According to Pinto and Menzies (2011:30), the occurrence of rare, spontaneous 
mutations during replication of the TB bacillus is a natural phenomenon, but the 
preferential selection and propagation of such resistant mutants is man-made, and 
largely preventable.  
 
Development of a poster 
 
A poster will be developed for presentation of the study and its findings to interest 
groups. The poster will cover the content of research purpose, research question, 
objectives, data collection, data analysis, presentation of the findings and 
recommendations. 
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5.3.2 Implications relating to nursing practice 
 
The implications of these findings to nursing practice are as follows:  
 
Emphasise should be on ensuring that TB patients are properly treated and adherence 
counselling for patients at every contact with patient should be ensured during the initial 
treatment. It is important that the adherence counselling of TB patients be as aggressive 
as the one in HIV care, where the patients are provided 3 counselling sessions prior to 
treatment initiation, and during follow up visits to have a one on one counselling session 
prior to refill of medication and in case of suspicion of default the patient is provided 
stepped up intensified counselling and potential risks discussed with patient. This 
system has worked quite well for HIV care and may need to be adopted for the TB 
programme. 
 
The study showed a significant association between development of side effects during 
TB treatment and progression to DR TB, which brings up the need for the health care 
workers to stay alert of patients who have been initiated on TB treatment presenting to 
their facilities. Patient empowerment on not waiting at home with any side effect or 
adverse reaction to the medication but to report it immediately without waiting for the 
next scheduled appointment or visit. This would greatly minimize the side effects and 
patients would adhere to the medication better with reduced side effects. 
 
Infection prevention and control measures need to be strengthened in health care 
facilities, this includes the all the 3 measures: administrative (policies and procedures), 
environmental (opening of windows, doors, designing patient flow) and personal 
protection (use of masks, gloves). 
 
Implications relating to education 
 
The education of health care workers and health care students should include 
Tuberculosis as a module at the nursing and medical schools. Currently the nursing 
curriculum does not have tuberculosis as a standing module and as a result students 
complete their education with little knowledge on the TB management subject. Pre 
service training on TB has already been identified as lacking in the country’s nursing 
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curriculum and equipping the students with knowledge on management on tuberculosis 
will address a lot of issues. 
 
Implications relation to research 
 
Research needs to be continued to understand the extant that the TB bacteria has 
evolved over the coming years through constant mutations and exposure to the TB 
drugs. The results in this study has already shown that over the years drug resistant TB 
has become more a direct infection than due to previous exposure to TB drugs, the 
factors contributing to this have to be further investigate, could this be due to TB 
bacteria evolving over the years as a result TB is becoming more resistant or is due to 
the increased pool of patients with poor adherence resulting in the resistant bacteria 
increasing, another possibility could be that as a result of the introduction of Expert 
testing as a first diagnostic test in the country more yield of patients is identified which 
before microscopy was only identifying as positive to TB but unable to categorise as 
resistant. 
 
Implications to public health 
 
The results from the study showed that infection mostly happens through transmission 
from an infected individual to an uninfected individual. This suggests as recommended 
above that infection prevention and control measures in the health facility and also in 
the community is very important. TB has been seen to affect one family member to the 
next and this has been due to poor IPC measures at the family and community settings. 
The need for the government to ensure that the rights of the people infected by TB are 
protected cannot be overly emphasized as stigma was seen to play a large role and fear 
of losing jobs which majority of the patients infected with TB eventually lost may be 
another factor that results in continued TB spread at work settings. The country also has 
no bill protecting the public from a patient that refuses to take his TB medication and the 
individual can continue working without treatment and continue transmitting the TB to 
unsuspecting work colleagues. 
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5.4 CONCLUSION 
 
Based on the findings of this study into factors influencing the trend of DR-TB, we are 
able to conclude the following: 
 
Previous treatment history has influence in the development of DR-TB as shown in the 
study results from comparison of the 2 cohorts. In cohorts, the participants and the 
reviewed records it shows that prior exposure to FLD’s was a common denominator and 
this confirms that patients that have been previously treated for TB once have an 
increased probability of developing drug resistant tuberculosis. The results of the 
retrospective data (2012-2015) shows that in the past years the main cause for DR-TB 
was previous treatment with FLD’s (these were patients that had completed treatment) 
but the analysis of current patients on DR-TB showed that there was evolution in the 
transmission of DR-TB where direct transmission is increasing showing that the DR-TB 
patients in the communities are now directly passing the disease to others (close 
contacts). 
 
The researcher’s interpretation was that there was an increase in direct transmission of 
drug resistant TB in our communities over the years almost to the same level as 
previous treatment. This was suggested by that there was an increase in drug resistant 
cases reporting that they have never been treated for TB before from the interviewed 
participants. 
 
As much a previous treatment is a factor for DR-TB, but direct transmission is on the 
rise and may eventually be the major transmitter of DR-TB surpassing prior treatment. 
This leads recommending strengthening of IPC measures including development of 
policies, IPC work-plans and personal protection to curb the evident gradual increase in 
direct transmission of DR-TB. 
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DEPARTMENT OF HEALTH STUDIES, UNISA 
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ANNEXURE B 
 
LETTER OF REQUEST FOR PERMISSION TO  
CONDUCT THE STUDY 
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LETTER OF REQUEST FOR PERMISSION TO CONDUCT THE STUDY 
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ANNEXURE C 
 
PERMISSION GRANTED TO CONDUCT THE STUDY 
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PERMISSTION GRANTED TO CONDUCT THE STUDY 
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ANNEXURE D 
 
CONSENT FORM 
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CONSENT FORM 
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ANNEXURE E 
 
DATA COLLECTION TOOLS 
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DATA COLLECTION TOOLS:  QUESTIONNAIRE 
 
Risk Factors influencing the epidemiology of drug resistant tuberculosis patients 
enrolled for treatment at the National Tuberculosis Referral Hospital, Swaziland 
All information herewith provided will be treated confidentially. It is not necessary 
to indicate your name on this questionnaire 
 
          INSTRUCTIONS   
1. Answer all questions by providing an “X” in the box corresponding to the chosen 
alternative  
2. Answer all questions as honestly, frankly and objectively  as possible 
3. Answer according to your own personal opinion, knowledge and experience 
 
 
Answer the question by placing an “X” in the box corresponding to the 
alternative which is applicable to you  
                          
SECTION A: BIOGRAPHICAL DATA 
 
 
Ref no: 
 
 
   
               3 
 
 
Today’s date: 
 
 
Day Month Year 
        
 
      
                9 
 
 
1.  
 
In which age category do you fall? 
 
1  10-19  
2  20-29  
3  30-39  
4   40-49  
5  50-59  
6   60+  
 
 
 
                  10 
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2.  
 
What is your marital status? 
 
1 Single  
2 Married  
3 Cohabiting  
4 Other  
 
 
 
 
 
 
 
11 
3 
 
 
 
 
What is your gender? 
 
Male 
 
 
Female 
 
12 
      4 
Indicate the highest grade passed 
 
1 Grade 7  
2 Grade 10  
3 Grade 12  
4 Other (specify)  
 
 
 
          13 
 
     5 
Indicate who you live with 
 
1 Family with both parents  
2 Single parent family  
3 Sibling-headed family  
4 Alone  
5 Other (specify)  
 
 
 
 
 
            14 
     6 
 What is your position in the family? 
 
1 First born  
2 Second born  
3 Third born  
3 Last born  
4 Other (specify0  
 
 
 
 
 
 
           15 
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     7 
Which region are you from? 
 
 
1 Manzini  
2 Hhohho  
3 Shiselweni  
4 Lubombo  
 
 
16 
                                                                                                       1-16 
 
 
Please comment on the following aspects from B-F by placing an “X” on the choice that 
best reflects your opinion about the topic under discussion 
 
 
SECTION B: GRAND TOUR QUESTION 
 
“What could be the risk factors that resulted in you having DR-TB?”  
 
 
 
 
 
                                                                                                                     
 
 
THANK YOU FOR YOUR PARTICIPATION 
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ANNEXURE F 
 
TRANSCRIPTION 
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TRANSCRIPTION 
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ANNEXURE G 
 
LETTER FROM STATISTICIAN 
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LETTER FROM STATISTICAIN 
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ANNEXURE H 
 
CHECKLIST TO COLLECT DATA FROM DOCUMENTS 
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CHECKLIST TO COLLECT DATA FROM DOCUMENTS 
 
 
Type of document (check one) 
o Newspaper 
o Letter 
o Memorandum 
o Report 
o register 
              
2.  
Unique physical characteristics of the document (check at least one or more) 
o handwritten 
o typed  
o interestingly letter-headed 
o other 
              
3.  
Dates of document 
 
 
              
4. 
Author 
 
 
Position 
 
 
              
5. 
For what audience was the document written? 
              
6. 
 
List key areas touched by the document. List from the document, 
 
Why do you think the document was written? 
 
 
 
 
 
              
7. 
Fill in information captured by the document 
 
Patient Distribution by Age and Sex 
 
SEX 0-
4 
5-
14 
15-
20 
21-
25 
26-
30 
31-
35 
36-
40 
41-
45 
46-
50 
51-
55 
56-
60 
60+ 
Male             
Female             
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8. 
Resistance Pattern by Age and Sex 
 
SEX 0-
4 
5-
14 
15+ 0-
4 
5-
14 
15+ 
 Male Female 
Mono 
Resistance 
      
Poly 
resistance 
      
Rif only       
MDR        
XDR       
 
              
9.  
Patient Distribution by Region 
 
Region Male Female 
Hhohho   
Manzini   
Lubombo   
Shiselweni   
 
            
10.  
 
Patient distribution by disease type 
 
Disease Type SEX 
Male Female 
Mono Resistance   
Poly resistance   
Rif only   
MDR    
XDR   
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11. 
 
Previous Treatment History by Site (at initiation) 
 
Disease by Site  SEX 
Male Female 
Pulmonary   
Extra Pulmonary   
 
 
            
12. 
 
 
Previous Treatment History by Sex 
 
History of Treatment Male Female 
Previously treated for TB (FLD)   
Previously treated for TB (SLD)   
No previous history of TB (New)   
 
 
            
13. 
 
If previously treated  
 
Risk Category Male Female 
New: smear + (HIV)   
Failure to convert at2/3 mnths of treatment   
Treatment Failure category 1   
Treatment Failure Category 2   
Relapse   
Default   
Contact to DR patient   
Mine worker   
Health Worker   
Prisoner   
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14. 
 
Resistance by HIV Status 
 
Disease Type HIV STATUS 
 Positive  Negative Unknown 
Mono Resistance    
Poly resistance    
Rif only    
MDR     
XDR    
 
 
            
15. 
Resistanc
e by ART 
Uptake by 
Sex 
 
 
 
Disease Type ART UPTAKE 
 Not initiated  Defaulted  Initiated on ART 
M F M F M F 
Mono Resistance       
Poly resistance       
Rif only       
MDR        
XDR       
 
            
16. 
 
Resistance in relation to other co-
morbidities 
 
Comorbidities Male Female 
Asthma   
Diabetes   
Heart conditions   
RTI’s other than TB   
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